WO2020114358A1 - Cd19抗体及其应用 - Google Patents

Cd19抗体及其应用 Download PDF

Info

Publication number
WO2020114358A1
WO2020114358A1 PCT/CN2019/122486 CN2019122486W WO2020114358A1 WO 2020114358 A1 WO2020114358 A1 WO 2020114358A1 CN 2019122486 W CN2019122486 W CN 2019122486W WO 2020114358 A1 WO2020114358 A1 WO 2020114358A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/122486
Other languages
English (en)
French (fr)
Inventor
董军纪
陈超
于婷婷
徐乐
危喜玲
李志广
李想
曾怡
李少燕
陈小锋
李文佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of WO2020114358A1 publication Critical patent/WO2020114358A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Definitions

  • the present application relates to the field of biomedicine, in particular to an antibody or antigen-binding fragment that specifically binds to CD19 protein.
  • B lymphocyte antigen CD19 also known as CD19 molecule (differentiation cluster 19).
  • CD19 is expressed in B cells of the germinal center and large dendritic cells in the follicular dendritic cells, mantle cells, and T cell regions between follicles.
  • CD19 plays two main roles in human B cells, one is to act as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and the other is to act within the CD19/CD21 complex to lower the threshold of the B cell receptor signaling pathway .
  • CD19 protein is a target protein that exists stably on the surface of B lymphocytes. It exists in all stages of B cell maturation.
  • CD19 has become an important target for the treatment of hematoma-related tumors.
  • CD19 antibodies have low specificity and limited tumor suppressive capacity, so it is urgent to develop new anti-CD19 drugs for new drug development.
  • the present application provides an antibody or antigen-binding fragment that specifically binds to CD19 and uses thereof.
  • the present application also provides a fusion protein comprising the antibody or antigen-binding fragment thereof, a nucleic acid molecule encoding the antibody or antigen-binding protein thereof, a vector containing the nucleic acid molecule, a cell containing the vector or the nucleic acid molecule, etc. .
  • the anti-CD19 antibody provided in this application has one or more of the following properties: 1) can specifically bind to the CD19 protein; 2) has different affinity characteristics for different epitopes of the CD19 protein; 3) has a good targeted killing effect ; 4) has higher stability; 5) has higher purity; 6) can be used to treat cancer.
  • the present application provides an antibody, antigen-binding fragment or variant thereof that binds to CD19 protein with an IC 50 value of 3.5 ⁇ g/ml or lower.
  • the antibody is selected from any one of the group consisting of monoclonal antibodies, single chain antibodies, chimeric antibodies, murine antibodies, and humanized antibodies.
  • the antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant is selected from the group consisting of: 1) a protein or polypeptide substituted, deleted, or added with one or more amino acids in the antibody or the antigen-binding fragment thereof; and 2) with The antibody or the antigen-binding fragment of the protein or polypeptide has more than 90% sequence homology.
  • the present application provides an antibody, antigen-binding fragment or variant thereof, which competes with a reference antibody for binding to the CD19 protein
  • the reference antibody comprises light Chain variable region and heavy chain variable region
  • the light chain variable region of the reference antibody comprises LCDR1-3
  • the amino acid sequence of the LCDR1 is selected from the amino acid sequence shown in any one of the following group: SEQ ID NO : 4 and SEQ ID NO: 18
  • the amino acid sequence of the LCDR2 is selected from the amino acid sequences shown in any of the following groups: SEQ ID NO: 5 and SEQ ID NO: 19
  • the LCDR3 amino acid sequence is selected from The amino acid sequence shown in any of the following group: SEQ ID NO: 6 and SEQ ID NO: 20
  • the heavy chain variable region of the reference antibody comprises HCDR1-3
  • the amino acid sequence of the HCDR1 is selected from The amino acid sequence shown in any one of the groups: SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32; the amino acid sequence of the HC
  • the amino acid sequence of the light chain variable region of the reference antibody is selected from the amino acid sequences shown in any of the following groups: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO :46
  • the amino acid sequence of the heavy chain variable region of the reference antibody is selected from the amino acid sequences shown in any of the following groups: SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52.
  • the antibody 3.5 ⁇ g / ml or less of IC 50 values combined with the CD19 protein.
  • the antibody is selected from any one of the group consisting of monoclonal antibodies, single chain antibodies, chimeric antibodies, murine antibodies, and humanized antibodies.
  • the antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant is selected from the group consisting of: 1) a protein or polypeptide substituted, deleted, or added with one or more amino acids in the antibody or the antigen-binding fragment thereof; and 2) with The antibody or the antigen-binding fragment of the protein or polypeptide has more than 90% sequence homology.
  • the present application provides an antibody, antigen-binding fragment or variant thereof
  • the antibody, antigen-binding fragment or variant thereof comprises LCDR1
  • the LCDR1 comprises an amino acid selected from any one of the following group Sequence: SEQ ID NO: 4 and SEQ ID NO: 18.
  • it comprises LCDR2
  • the LCDR2 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 5 and SEQ ID NO: 19.
  • it includes LCDR3
  • the LCDR3 includes an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 6 and SEQ ID NO: 20.
  • it comprises a light chain variable region VL
  • the light chain variable region VL comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 42, SEQ ID NO: 44 And SEQ ID NO: 46.
  • the HCDR1 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32.
  • it comprises HCDR2, and the HCDR2 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 8, SEQ ID NO: 22, and SEQ ID NO: 33.
  • it comprises HCDR3, and the HCDR3 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 9 and SEQ ID NO: 23 and SEQ ID NO: 34.
  • it comprises a heavy chain variable region VH, and the heavy chain variable region VH comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 48, SEQ ID NO: 50 And SEQ ID NO: 52.
  • the antibody or antigen-binding fragment thereof is scFv.
  • the scFv comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 56, SEQ ID NO: 58 and SEQ ID NO: 60.
  • the antibody 3.5 ⁇ g / ml or less of IC 50 values combined with the CD19 protein.
  • the antibody is selected from any one of the group consisting of monoclonal antibodies, single chain antibodies, chimeric antibodies, murine antibodies, and humanized antibodies.
  • the antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant is selected from the group consisting of: 1) a protein or polypeptide substituted, deleted, or added with one or more amino acids in the antibody or the antigen-binding fragment thereof; and 2) with The antibody or the antigen-binding fragment of the protein or polypeptide has more than 90% sequence homology.
  • the CD19 protein is mouse CD19 protein.
  • the present application provides a fusion protein comprising the antibody, antigen-binding fragment or variant thereof described herein.
  • the fusion protein is a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an extracellular hinge region, a transmembrane domain, a costimulatory domain, and a CD3 ⁇ intracellular signal transduction domain.
  • the extracellular hinge region is selected from CD8 hinge or IgG4 hinge.
  • the transmembrane domain is selected from the ⁇ , ⁇ , or ⁇ chain of the T cell receptor, CD28, CD3e, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64 , CD80, CD86, CD134, CD137 and CD154. In certain embodiments, the transmembrane domain is selected from CD8-1 or CD8-2.
  • the costimulatory domain is selected from CD27, CD28, 4-1BB, OX40, or ICOS.
  • the extracellular hinge region is selected from a CD8 hinge or an IgG4 hinge; the transmembrane domain is selected from CD8-1 or CD8-2; the co-stimulation The domain is selected from 4-1BB or OX40.
  • the N-terminus of the CD8-1 transmembrane is connected to the C-terminus of the CD8 hinge, and the C-terminus of the CD8-1 transmembrane is linked to the 4
  • the N terminal of -1BB is connected
  • the C terminal of 4-1BB is connected to the N terminal of OX40
  • the C terminal of OX40 is connected to the N terminal of CD3 ⁇ .
  • the N-terminus of the CD8-2 transmembrane is connected to the C-terminus of the IgG4 hinge, and the C-terminus of the CD8-2 transmembrane is linked to the 4
  • the N terminal of -1BB is connected
  • the C terminal of 4-1BB is connected to the N terminal of OX40
  • the C terminal of OX40 is connected to the N terminal of CD3 ⁇ .
  • the present application provides isolated one or more nucleic acid molecules that encode the antibodies, antigen-binding fragments or variants described herein, and/or that encode the fusion proteins described herein.
  • the present application provides one or more vectors, which comprise one or more nucleic acid molecules described in the present application.
  • the present application provides one or more cells comprising one or more nucleic acid molecules described herein or one or more vectors described herein.
  • the present application provides a method for preparing the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein described in the present application.
  • the antigen-binding fragments or variants thereof, and/or the cells described herein are cultured under the conditions for the expression of the fusion protein described herein.
  • the methods described herein include harvesting the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein.
  • the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody described herein, its antigen-binding fragment or variant, the nucleic acid molecule described herein, the vector described herein, and the application described herein Cells and/or fusion proteins described herein, and optionally pharmaceutically acceptable adjuvants.
  • the present application provides the antibody, antigen-binding fragment or variant thereof, and/or the use of the fusion protein in the preparation of a medicament for preventing or treating a disease or disorder.
  • the disease or disorder is selected from any one of the group consisting of tumors and autoimmune diseases.
  • the tumor is selected from any one of the group consisting of B-cell subtype non-Hodgkin's malignant lymphoma (NHL), Burkitt's lymphoma, multiple myeloma, pre-B Acute lymphoblastic leukemia and other malignant lung tumors derived from early B-cell precursors, common acute lymphocytic leukemia, T chronic lymphocytic leukemia, hairy cell leukemia, non-acute lymphoblastic leukemia, Fahrenheit macroglobulin blood Disease, prolymphocytic leukemia, plasmacytoma, osteosclerotic myeloma, plasmacytic leukemia, monoclonal gammopathy (MGUS), smoldering multiple myeloma (SMM), chronic multiple myeloma (IMM) ), Hodgkin's malignant lymphoma, gastric cancer, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer,
  • NHL B
  • the autoimmune disease is selected from any one of the group consisting of rheumatoid arthritis, multiple sclerosis, and CD19 + leukemia.
  • the present application provides a method for inhibiting the biological activity of CD19 protein, which comprises administering the antibody, antigen-binding fragment or variant thereof, the nucleic acid molecule, the carrier, the carrier Cells and/or the fusion protein.
  • the application provides the antibody, antigen-binding fragment or variant thereof, the nucleic acid molecule, the carrier, the cell and/or the fusion protein described in the application Application of reagents for detecting tumors.
  • Figure 1 shows the ELISA activity detection results of the CD19 antibody described in this application.
  • Figure 2 shows the results of the CD19 antibody flow cytometry assay described in this application.
  • Figure 3 shows the detection results of the CD19 antibody Western blot method described in this application.
  • Fig. 4 shows the results of the flow cytometry detection of the CD19 antibody described in this application at different concentrations.
  • FIG. 5 shows a schematic diagram of the CAR structure constructed in the embodiment of the present application.
  • Figure 6 shows the test results of anti-CD19CAR-T positive rate.
  • the present application provides an antibody that can specifically bind to CD19 protein, which can specifically bind to CD19 protein and possess different affinity characteristics for different epitopes of CD19.
  • the CD19 antibody has good targeted killing effect, higher stability, and higher purity.
  • the CD19 antibody can be used to treat cancer.
  • an antibody generally refers to a polypeptide molecule that can specifically recognize and/or neutralize a specific antigen.
  • an antibody may include an immunoglobulin composed of at least two heavy (H) chains and two light (L) chains connected to each other by a disulfide bond, and include any molecule that includes an antigen binding portion thereof.
  • the term “antibody” includes monoclonal antibodies, antibody fragments, or antibody derivatives, including but not limited to human antibodies, humanized antibodies, chimeric antibodies, single domain antibodies (eg, dAbs), single chain antibodies (eg, scFv), And antibody fragments that bind to the antigen (eg, Fab, Fab' and (Fab) 2 fragments).
  • the term “monoclonal antibody” (monoclonal antibody) (mAb) generally refers to an antibody produced by only one type of immune cell, and can also be produced by the fusion of the immune cell that makes this antibody and cancer cells Hybridoma cells are produced.
  • the term “single chain antibody” (single chain antibody) (sFv) generally refers to an antibody composed of an antibody heavy chain variable region and a light chain variable region connected by a linker. ScFv can better retain its affinity for antigen, and has the characteristics of small molecular weight, strong penetration and weak antigenity.
  • humanized antibody generally refers to an antibody re-expressed by murine monoclonal antibody modified by gene cloning and DNA recombination technology, most of its amino acid sequence is replaced by human sequence, and the parent mouse monoclonal is basically retained The affinity and specificity of the antibody, which reduces its heterogeneity, is beneficial to the human body.
  • chimeric antibody generally refers to an antibody composed of the V region gene of a murine antibody and the C region gene of a human antibody, because it reduces the components of the murine origin, thereby reducing the murine origin Adverse reactions caused by sexual antibodies and help improve efficacy.
  • murine antibody generally refers to the fusion of B cells derived from immunized mice with myeloma cells, and then selecting a mouse hybrid fusion cell that can both wirelessly propagate and secrete antibodies, and Screening, antibody preparation and purification.
  • antibody also includes all recombinant forms of antibodies, such as antibodies expressed in prokaryotic cells as well as any antibody fragments and derivatives thereof that bind to antigens described herein.
  • Each heavy chain may be composed of a heavy chain variable region (VH) and a heavy chain constant region.
  • Each light chain may be composed of a light chain variable region (VL) and a light chain constant region.
  • VH and VL regions can be further divided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • Each VH and VL may be composed of three CDRs and four FR regions, and they may be arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • the variable regions of the heavy and light chains contain binding domains that interact with the antigen.
  • the constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component of the classical complement system (Clq).
  • antibody binding fragment generally refers to one or more fragments of an antibody that perform the function of specifically binding an antigen.
  • the antigen-binding function of an antibody can be achieved by the full-length fragment of the antibody.
  • the antigen-binding function of an antibody can also be achieved by the following fragments: (1) Fab fragment, that is, a monovalent fragment composed of VL, VH, CL, and CH domains; (2) F(ab') 2 fragment, including A bivalent fragment of two Fab fragments connected by a disulfide bond at the hinge region; (3) Fd fragments composed of VH and CH domains; (4) Fv fragments composed of VL and VH domains of one arm of an antibody; (5) A dAb fragment composed of VH domains (Ward et al., (1989) Nature 341: 544-546); (6) the isolated complementarity determining region (CDR) and (7) two optionally connected by a linker A combination of three or more separate CDRs.
  • CDR complementarity determining region
  • the "antigen binding portion” may also include an immunoglobulin fusion protein, the fusion protein comprising a binding domain selected from: (1) a binding domain polypeptide fused to an immunoglobulin hinge region polypeptide; (2) CH2 constant region of the immunoglobulin heavy chain fused to the hinge region; and (3) CH3 constant region of the immunoglobulin heavy chain fused to the CH2 constant region.
  • an antibody specifically binding to CD19 protein provided by the present application, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of Fab, scFv, Fab', F(ab)2, F(ab')2 and dAb .
  • CD19 protein generally refers to a transmembrane glycoprotein unique to the B cell line of about 95 kDa that is mainly expressed in early B cells.
  • CD19 protein is expressed in normal and malignant B lymphocytes and is regarded as the most reliable surface marker during B cell development.
  • the CD19 protein may be a human CD19 protein.
  • the human CD19 protein expressed in the present application may include the amino acid sequence shown in NCBI accession number AAB60697.
  • the CD19 protein may be a CD19 recombinant protein, and the recombinant protein may be the extracellular region of the CD19 protein.
  • the CD19 recombinant protein may be ab234966 of abcam, a protein with amino acid sequence numbers from 20 to 291.
  • fusion protein is also referred to as chimeric protein (chimeric protein), and usually refers to the expression product of two genes obtained by DNA recombination technology after recombination.
  • Fusion protein technology is a purposeful gene fusion and protein expression method for obtaining a large number of standard fusion proteins. Using fusion protein technology, it is possible to construct and express novel target proteins with multiple functions. Translation of the fusion gene produces a single or multiple polypeptides with the functional properties of each original protein of the derivat.
  • the recombinant fusion protein artificially produced by recombinant DNA technology can be used for biological research or treatment.
  • the chimera or chimera generally represents a fusion protein made of polypeptides with different functions or physicochemical characteristics.
  • the fusion protein may include a chimeric antigen receptor formed by fusing the antigen-binding region scFv, CD3 ⁇ chain or intracellular part of the antibody, which may include tumor-associated antigen-binding region, extracellular hinge region, transmembrane region and other domains.
  • the tumor-associated antigen-binding region can be derived from the antigen-binding region of an antibody, such as scFv.
  • chimeric antigen receptor is a fusion protein of the variable region of a single chain antibody and a T cell signaling molecule. It allows T cells to recognize specific antigens in a non-MHC-restricted manner and exert a killing effect.
  • single-chain antibody may be an antibody composed of the heavy chain variable region and the light chain variable region connected by a linker peptide.
  • CAR is the core component of chimeric antigen receptor T cells (CAR-T), which may include CD19 binding domain, transmembrane domain, costimulatory domain and intracellular signal transduction domain.
  • transmembrane domain generally refers to a domain in CAR that passes through a cell membrane, which is connected to an intracellular signal transduction domain and plays a role in transmitting signals.
  • costimulatory domain generally refers to an intracellular domain that can provide an immunocostimulatory molecule that is a cell surface molecule required for an effective response of lymphocytes to an antigen.
  • intracellular signaling domain generally refers to a component of CAR signaling located in a cell, which includes a signaling domain and a domain that specifically binds to the receptor component, for example: It can be selected from CD3 ⁇ intracellular domain, CD28 intracellular domain, 4-1BB intracellular domain and OX40 intracellular domain.
  • variants related to antibodies means in the present application that it has been substituted by at least 1, such as 1-30, or 1-20 or 1-10, such as 1 or 2 or 3 or 4 or 5 amino acids, Antibodies with deletion and/or insertion that have a target antibody region of amino acid changes (eg, heavy chain variable region or light chain variable region or heavy chain CDR region or light chain CDR region), where the variant substantially retains the antibody before the change Molecular biological properties.
  • this application encompasses any antibody variants described in this application.
  • the antibody variant retains at least 60%, 70%, 80%, 90%, or 100% of the biological activity (eg, antigen binding capacity) of the pre-altered antibody.
  • the change does not cause the antibody variant to lose its binding to the antigen, but optionally can impart properties such as increased antigen affinity and different effector functions.
  • the heavy chain variable region or light chain variable region, or each CDR region of an antibody may be changed individually or in combination.
  • the amino acid changes in one or more or all three heavy chain CDRs are no more than 1, 2, 3, 4, 5, 6, 6, 7, 8, 9 Or 10.
  • the amino acid change may be an amino acid substitution, for example, it may be a conservative substitution.
  • the antibody variant has at least 80%, 85%, 90%, or 95% or 99% or higher amino acid identity over the antibody sequence region of interest.
  • the term "isolated” generally refers to an antibody that has been separated from components in its natural environment.
  • the antibody is purified to greater than 95% or 99% purity by, for example, electrophoresis (eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (eg, ion exchange or Reverse phase HPLC).
  • electrophoresis eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatography eg, ion exchange or Reverse phase HPLC
  • nucleic acid molecule generally refers to an isolated form of nucleotides, deoxyribonucleotides or ribonucleotides of any length, isolated from its natural environment or artificially synthesized, or analogs thereof.
  • the nucleic acid molecules described in this application may be isolated. For example, it can be produced or synthesized by: (i) amplified in vitro, such as polymerase chain reaction (PCR) amplification, (ii) cloned and recombinantly produced, (iii) purified , Such as by enzyme digestion and gel electrophoresis fractionation, or (iv) synthetic, for example by chemical synthesis.
  • PCR polymerase chain reaction
  • the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA technology.
  • nucleic acids encoding the antibodies or antigen-binding fragments thereof can be prepared by a variety of methods known in the art. These methods include, but are not limited to, the use of restriction fragment manipulation or the use of synthetic oligonucleotides Overlapping extension PCR, specific operations can be found in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausube et al. Current Protocols Molecular Biology, Greene Publishing and Wiley-Interscience, New York, 1993.
  • the term "vector” generally refers to a nucleic acid molecule capable of self-replication in a suitable host to transfer the inserted nucleic acid molecule into and/or between host cells.
  • the vector may include a vector mainly used for inserting DNA or RNA into a cell, a vector mainly used for replicating DNA or RNA, and a vector mainly used for expression of transcription and/or translation of DNA or RNA.
  • the carrier also includes carriers having multiple functions described above.
  • the vector may be a polynucleotide capable of being transcribed and translated into a polypeptide when introduced into a suitable host cell. Generally, by culturing a suitable host cell containing the vector, the vector can produce the desired expression product.
  • the vector may also contain other genes, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions.
  • the vector may also contain expression control elements that allow the coding region to be correctly expressed in a suitable host.
  • control elements are well known to those skilled in the art. For example, they may include promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation.
  • the expression control sequence is an adjustable element.
  • the specific structure of the expression control sequence may vary according to the function of the species or cell type, but usually contains 5'untranscribed sequences and 5'and 3'untranslated sequences involved in transcription and translation initiation, such as TATA box, Cap sequence, CAAT sequence, etc.
  • the 5' non-transcriptional expression control sequence may comprise a promoter region, and the promoter region may comprise a promoter sequence for transcriptional control of functionally linked nucleic acids.
  • the term "cell” generally refers to an individual cell or cell that can express the antibody, antigen-binding fragment or variant thereof described herein, and can or already contains a plasmid or vector including the nucleic acid molecule described herein Line or cell culture.
  • the cells may be prokaryotic cells (such as E. coli) or eukaryotic cells (such as yeast cells, COS cells, Chinese hamster ovary (CHO) cells, HeLa cells, HEK293 cells, COS-1 cells, NS0 cells or bone marrow Tumor cells).
  • the cell may be an immune cell.
  • pharmaceutically acceptable adjuvant generally refers to a pharmaceutically acceptable formulation carrier, solution, or additive that enhances the properties of the formulation.
  • additives are well known to those skilled in the art.
  • cancer generally refers to or describes the physiological condition of a mammal, which is typically characterized by unregulated cell proliferation or survival.
  • hyperproliferative diseases called cancer include, but are not limited to, solid tumors, such as occur in breast, respiratory tract, brain, reproductive organs, digestive tract, urethra, eyes, liver, skin, head and neck, thyroid, parathyroid Cancer of the glands, and their distant metastasis.
  • diseases also include lymphoma, sarcoma and leukemia.
  • breast cancer include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, breast ductal carcinoma in situ, and breast lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to, small cell lung cancer and non-small cell lung cancer, as well as bronchial adenoma and pleural lung blastoma.
  • brain cancer include, but are not limited to, brain stem and hypothalamic keratinoma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, and neuroectodermal and pineal tumors.
  • Male genital tumors include but are not limited to prostate and testicular cancer.
  • Female genital tumors include but are not limited to endometrial cancer, cervical cancer, ovarian cancer, vaginal cancer and vulvar cancer, as well as uterine tumors.
  • Gastrointestinal tumors include but are not limited to anal, colon, colorectal, esophageal, gallbladder, stomach, pancreas, rectum, small intestine, and salivary gland cancers.
  • Urethral tumors include but are not limited to bladder, penis, kidney, renal pelvis, ureter, and urethral cancer.
  • Eye cancers include but are not limited to intraocular melanoma and retinoblastoma.
  • liver cancer include, but are not limited to, hepatocellular carcinoma (hepatocellular carcinoma with or without fibrous lamellar variation), cholangiocarcinoma (intrahepatic cholangiocarcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma type skin cancer.
  • Head and neck cancers include but are not limited to laryngeal/ hypopharyngeal/nasopharyngeal/oropharyngeal cancers, and lips and oral cavity cancers.
  • Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and central nervous system lymphoma.
  • Sarcomas include, but are not limited to, soft tissue sarcoma, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include but are not limited to acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and hairy cell leukemia.
  • autoimmune disease generally refers to an autoimmune disease that refers to a disease caused by an immune response of the body to self-antigens that causes damage to its own tissues.
  • the immune system defends the body from invasion (recognition) by foreign or dangerous substances, including microorganisms, parasites, malignant tumor cells, and transplanted organs and tissues. Under normal circumstances, the immune system only reacts to foreign or dangerous substances, but does not react to antigens in its own tissues. However, sometimes there is abnormal immune function, which treats its own tissues as foreign, and produces antibodies (called autoantibodies) or immune cells to attack its own cells or tissues. This response is called an autoimmune response. It causes inflammation and tissue damage.
  • autoimmune diseases may cause autoimmune diseases, but some people produce very little autoantibodies without autoimmune diseases.
  • Common autoimmune diseases include rheumatoid arthritis, multiple sclerosis, and CD19 + leukemia. Additional diseases considered to be autoimmune include Addison's disease, polymyositis, Syndrome, progressive systemic sclerosis, multiple cases of glomerulonephritis (kidney inflammation) and some cases of infertility.
  • the term "about” generally refers to a range of 0.5%-10% above or below the specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, above or below the specified value 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%.
  • the present application provides an antibody, antigen-binding fragment or variant thereof, which may be 3.5 ⁇ g/mL or less (eg, 3.5 ⁇ g/ml or less, 3.4 ⁇ g/mL or less, 3.3 ⁇ g/mL or more Low, 3.2 ⁇ g/mL or lower, 3.15 ⁇ g/mL or lower, 3.1 ⁇ g/ml or lower, 3.0 ⁇ g/mL or lower, 2.9 ⁇ g/mL or lower, 2.8 ⁇ g/mL or lower, 2.5 ⁇ g / mL or less, or 2.1 ⁇ g / mL or less) and IC 50 values with CD19 binding proteins.
  • the IC 50 value is determined by an ELISA method, and the IC 50 value may be 3.12 ⁇ g/mL or lower.
  • the antibody, antigen-binding fragment or variant thereof may be 5 ⁇ g/mL or lower (eg, 5 ⁇ g/mL or lower, 4.5 ⁇ g/mL or lower, 4 ⁇ g/mL or lower, 50 value of 3.5 ⁇ g / mL or less, 3 ⁇ g / mL or less, 2.5 ⁇ g / mL or less, 2 ⁇ g / mL or less, 1.5 ⁇ g / mL or less, 1 ⁇ g / mL or less) and an IC CD19 protein combined.
  • the IC 50 value is determined by flow cytometry, and the IC 50 value may be 5 ⁇ g/mL or less.
  • the antibody may be selected from any of the following group: monoclonal antibody, single chain antibody, chimeric antibody, murine antibody, and humanized antibody.
  • the antigen-binding fragment may be selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant may be selected from the following group: 1) One or more (eg, 1-2, 1-3) are substituted, deleted, or added to the antibody or the antigen-binding fragment thereof , 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10 or more) amino acid protein or polypeptide; and 2) More than 90% (eg, at least about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97) of the antibody or the antigen-binding fragment thereof %, about 98%, about 99% or more) of sequence homology protein or polypeptide.
  • the variant has substantially the same function as the antibody and its antigen-binding fragment (for example, it can specifically bind to the CD19 protein).
  • the antibody, antigen-binding fragment or variant thereof can compete with a reference antibody for binding to the CD19 protein.
  • the reference antibody may comprise a light chain variable region and a heavy chain variable region
  • the light chain variable region of the reference antibody may comprise LCDR1-3
  • the amino acid sequence of the LCDR1 may be selected from The amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 4 and SEQ ID NO: 18
  • the amino acid sequence of the LCDR2 may be selected from the amino acid sequence shown in any one of the following group or Variants: SEQ ID NO: 5 and SEQ ID NO: 19
  • the amino acid sequence of the LCDR3 can be selected from the amino acid sequences shown in any of the following groups or variants thereof: SEQ ID NO: 6 and SEQ ID NO :20
  • the heavy chain variable region of the reference antibody may include HCDR1-3
  • the amino acid sequence of the HCDR1 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof:
  • amino acid sequence of the HCDR2 may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 8, SEQ ID NO: 22 And SEQ ID NO: 33; and the amino acid sequence of the HCDR3 can be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 9, SEQ ID NO: 23 and SEQ ID NO: 34 .
  • sequence of the light chain variable region of the reference antibody may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46; the sequence of the heavy chain variable region of the reference antibody may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 48, SEQ ID NO: 50 and SEQ ID NO: 52.
  • the antibodies, antigen-binding fragments or variants thereof described herein may comprise antibody light chains or fragments thereof.
  • the light chain may include a light chain variable region, and the light chain variable region may include LCDR1, and the amino acid sequence of the LCDR1 may be selected from the amino acid sequence shown in any one of the following group or Variants: SEQ ID NO: 4 and SEQ ID NO: 18.
  • the light chain variable region may include LCDR2, and the amino acid sequence of the LCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 5 and SEQ ID NO: 19.
  • the light chain variable region may include LCDR3, and the amino acid sequence of the LCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 6 and SEQ ID NO: 20.
  • the light chain variable region of the antibody, antigen-binding fragment or variant thereof may comprise LFR1, and the amino acid sequence of the LFR1 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof : SEQ ID NO: 10, SEQ ID NO: 24 and SEQ ID NO: 35.
  • the light chain variable region may include LFR2, and the amino acid sequence of the LFR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 11 and SEQ ID NO: 25.
  • the light chain variable region may include LFR3, and the amino acid sequence of the LFR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 12 and SEQ ID NO: 26.
  • the light chain variable region may include LFR4, and the amino acid sequence of the FR4 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 13, SEQ ID NO: 27, and SEQ ID NO:36.
  • sequence of the light chain variable region may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 .
  • the antibodies, antigen-binding fragments or variants thereof described herein may comprise antibody heavy chains or fragments thereof.
  • the light chain may include a heavy chain variable region, and the heavy chain variable region may include HCDR1, and the amino acid sequence of the HCDR1 may be selected from the amino acid sequences shown in any one of the following groups or Variants: SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32.
  • the variable region of the heavy chain may comprise HCDR2, and the amino acid sequence of the HCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 8, SEQ ID NO: 22 and SEQ ID NO:33.
  • variable region of the heavy chain may include HCDR3, and the amino acid sequence of the HCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 9, SEQ ID NO: 23, and SEQ ID NO:34.
  • the heavy chain variable region of the antibody, antigen-binding fragment or variant thereof may include HFR1, and the amino acid sequence of the HFR1 may be selected from the amino acid sequences shown in any one of the following groups or variants thereof : SEQ ID NO: 14, SEQ ID NO: 28 and SEQ ID NO: 37.
  • the variable region of the heavy chain may include HFR2, and the amino acid sequence of the HFR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 15, SEQ ID NO: 29, and SEQ ID NO:38.
  • the heavy chain variable region may include HFR3, and the amino acid sequence of the HFR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 16, SEQ ID NO: 30, and SEQ ID NO:39.
  • the variable region of the heavy chain may include HFR4, and the amino acid sequence of the HFR4 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 17, SEQ ID NO: 31, and SEQ ID NO:40.
  • sequence of the variable region of the heavy chain may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52 .
  • the amino acid sequence of LCDR1 in the antibody or antigen-binding fragment thereof described herein may include SEQ ID NO: 4 or its variant; the amino acid sequence of LCDR2 may include SEQ ID NO: 5 or its variant ;
  • the amino acid sequence of LCDR3 may include SEQ ID NO: 6 or its variant; and the amino acid sequence of HCDR1 may include SEQ ID NO: 7 or its variant; the amino acid sequence of HCDR2 may include SEQ ID NO: 8 or its variant;
  • the amino acid sequence of HCDR3 may include SEQ ID NO: 9 or a variant thereof.
  • the antibody or antigen-binding fragment thereof may include antibody 25C5-2 or an antibody having the same LCDR1-3 and HCDR1-3 as it.
  • the amino acid sequence of LFR1 in the antibody or antigen-binding fragment thereof described in this application may include SEQ ID NO: 10 or its variant; the amino acid sequence of LFR2 may include SEQ ID NO: 11 or its variant; the amino acid sequence of LFR3 may include SEQ ID NO: 12 or its variant; the amino acid sequence of LFR4 may include SEQ ID NO: 13 or its variant; and the amino acid sequence of HFR1 may include SEQ ID NO: 14 or its variant; the amino acid sequence of HFR2 may include SEQ ID NO: 15 or a variant thereof; the amino acid sequence of HFR3 may include SEQ ID NO: 16 or a variant thereof; the amino acid sequence of HFR4 may include SEQ ID NO: 17 or a variant thereof.
  • the antibody or antigen-binding fragment thereof may include antibody 25C5-2 or antibodies having the same LFR1-4 and HFR1-4.
  • the light chain of the antibody or antigen-binding fragment thereof described herein may include a light chain variable region, and the amino acid sequence of the light chain variable region may include SEQ ID NO: 42 or a variant thereof ;
  • the heavy chain may comprise a heavy chain variable region, the amino acid sequence of the heavy chain variable region may include SEQ ID NO: 48 or a variant thereof.
  • the antibody or antigen-binding fragment thereof may include antibody 25C5-2 or an antibody having the same light chain variable region and heavy chain variable region as the same.
  • the antibody described in this application may be 25C5-2.
  • the amino acid sequence of LCDR1-3 of antibody 25C5-2 is shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively;
  • the amino acid sequence of LFR1-4 is SEQ ID NO: 10, SEQ respectively ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13;
  • VL amino acid sequence is shown in SEQ ID NO: 42;
  • HCDR1-3 amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9;
  • the amino acid sequences of HFR1-4 are shown in SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, respectively;
  • the amino acid sequence of VH is shown in SEQ ID NO: 48.
  • the antibody 25C5-2 may be scFv, and the scFv is VL-VH (that is, VL is connected to the N-terminus of VH through the linker peptide), wherein the amino acid sequence of the linker peptide may be as SEQ ID NO: 54 shows.
  • the amino acid sequence of the scFv may be as shown in SEQ ID NO: 56.
  • the antibody described in this application may be 10H10-1.
  • the amino acid sequence of LCDR1-3 of antibody 10H10-1 is shown in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 respectively;
  • the amino acid sequence of LFR1-4 is SEQ ID NO: 24 and SEQ respectively ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 27 are shown;
  • the amino acid sequence of VL is shown in SEQ ID NO: 44;
  • the amino acid sequences of HCDR1-3 are shown in SEQ ID NO: 21 and SEQ ID NO: 22 and SEQ ID NO: 23;
  • the amino acid sequences of HFR1-4 are shown in SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30 and SEQ ID NO: 31;
  • the amino acid sequence of VH is shown in SEQ ID NO: 50.
  • the antibody 10H10-1 may be scFv, and the scFv is VL-VH (that is, VL is connected to the N-terminus of VH through the linker peptide), wherein the amino acid sequence of the linker peptide may be as SEQ ID NO: 54 shows.
  • the amino acid sequence of the scFv may be as shown in SEQ ID NO: 58.
  • the antibody described in this application may be 16F10.
  • the amino acid sequences of LCDR1-3 of antibody 16F10 are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively;
  • the amino acid sequences of LFR1-4 are SEQ ID NO: 35, SEQ ID NO :11, SEQ ID NO:12 and SEQ ID NO:36;
  • VL amino acid sequence is shown as SEQ ID NO:46;
  • HCDR1-3 amino acid sequences are shown as SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO: 34;
  • the amino acid sequences of HFR1-4 are shown in SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40 respectively;
  • the amino acid sequence of VH is shown in SEQ ID NO :52 shown.
  • the antibody 16F10 may be scFv, and the scFv is VL-VH (that is, VL is connected to the N-terminus of VH through the linker peptide), wherein the amino acid sequence of the linker peptide may be as SEQ ID NO:54 shown.
  • the amino acid sequence of the scFv may be as shown in SEQ ID NO: 60.
  • the present application provides a fusion protein comprising the antibody, antigen-binding fragment or variant thereof.
  • the fusion protein may be a chimeric antigen receptor (CAR), which may include the antibody and T cell signaling molecule described in the present application.
  • CAR may include domains such as a CD19 binding domain, a transmembrane domain, a hinge region, a costimulatory domain, and an intracellular signal transduction domain.
  • the antibody may be a single chain antibody.
  • the antibody may comprise the amino acid sequence shown in SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60 or a functional variant thereof.
  • the single chain antibody may include 25C5-2, the amino acid sequence of which is shown in SEQ ID NO: 56.
  • the amino acid sequence of LCDR1-3 of single-chain antibody 25C5-2 is shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is shown in SEQ ID NO: 42; HCDR1-
  • the amino acid sequence of 3 is shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively; the amino acid sequence of VH is shown in SEQ ID NO: 48.
  • the single-chain antibody may include 10H10-1, and its amino acid sequence is shown in SEQ ID NO: 58.
  • the amino acid sequence of LCDR1-3 of single-chain antibody 10H10-1 is shown in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 respectively; the amino acid sequence of VL is shown in SEQ ID NO: 44; HCDR1-
  • the amino acid sequence of 3 is shown in SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 50.
  • the single-chain antibody may include 16F10, and its amino acid sequence is shown in SEQ ID NO: 60.
  • the amino acid sequences of LCDR1-3 of single-chain antibody 16F10 are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is shown in SEQ ID NO: 46; HCDR1-3
  • the amino acid sequence is shown in SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 52.
  • the CD19 binding domain may comprise an antibody, antigen-binding fragment or variant that specifically binds CD19.
  • the antibodies, antigen-binding fragments or variants thereof described herein may comprise antibody light chains or fragments thereof.
  • the light chain may include a light chain variable region, and the light chain variable region may include LCDR1, LCDR2, and LCDR3.
  • the amino acid sequence of the LCDR1 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 4 and SEQ ID NO: 18.
  • the amino acid sequence of the LCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 5 and SEQ ID NO: 19.
  • the amino acid sequence of the LCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 6 and SEQ ID NO: 20.
  • sequence of the light chain variable region may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 .
  • the light chain may include a heavy chain variable region, and the heavy chain variable region may include HCDR1, and the amino acid sequence of the HCDR1 may be selected from the amino acid sequences shown in any one of the following groups or Variants: SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32.
  • variable region of the heavy chain may comprise HCDR2, and the amino acid sequence of the HCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 8, SEQ ID NO: 22 and SEQ ID NO:33.
  • the variable region of the heavy chain may include HCDR3, and the amino acid sequence of the HCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 9, SEQ ID NO: 23, and SEQ ID NO:34.
  • sequence of the variable region of the heavy chain may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52 .
  • the CAR may include a hinge region, which may connect the antibody and the transmembrane domain.
  • the hinge region may be selected from CD8, whose amino acid sequence is shown in SEQ ID NO: 62; or it may be selected from IgG4, whose amino acid sequence is shown in SEQ ID NO: 64.
  • the CAR may include a transmembrane domain.
  • the transmembrane domain may be selected from the ⁇ , ⁇ , or ⁇ chain of the T cell receptor, CD28, CD3e, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86 , CD134, CD137 and CD154 and other polypeptides.
  • the transmembrane domain may be CD8-1, which may include the amino acid sequence shown in SEQ ID NO: 66 or a functional variant thereof; it may also be CD8-2, which may contain SEQ ID NO : The amino acid sequence shown in 68 or a functional variant thereof.
  • the CAR may include a costimulatory domain.
  • the costimulatory domain may be selected from polypeptides such as CD28, 4-1BB, OX40, and ICOS.
  • the costimulatory domain may be 4-1BB, which may contain the amino acid sequence shown in SEQ ID NO: 70 or a functional variant thereof; it may also be OX40, which may contain SEQ ID NO: 72. Shown amino acid sequence or functional variants.
  • the CAR may include a label detection signal
  • the label detection signal may be a fluorescent protein.
  • GFP GFP
  • RFP RFP
  • YFP YFP
  • the label detection signal may be located at the C-terminal of the CAR.
  • the CAR may include a Kozak sequence, the nucleotide sequence of which is shown in SEQ ID NO:1.
  • the Kozak sequence may be located at the N-terminus of the CAR.
  • the CAR may include a leader sequence whose nucleotide sequence is shown in SEQ ID NO: 2 (the nucleotide sequence does not include the Kozak sequence).
  • the leader sequence may be located at the N-terminus of the CAR.
  • the CAR of the present application may include a Kozak sequence, a leader sequence, a CD19 binding domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain in sequence from the N-terminus.
  • the CAR described in this application may include the Kozak sequence, the leader sequence, the CD19 binding domain, the transmembrane domain, the costimulatory domain, the intracellular signaling domain, and the label detection signal in sequence from the N-terminus .
  • the CAR described in this application may be CAR25C5-2, the amino acid sequence of LCDR1-3 is shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is SEQ ID NO: 42; the amino acid sequences of HCDR1-3 are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively; the amino acid sequence of VH is shown in SEQ ID NO: 48; VH and VL
  • the sequence of the connecting peptide between them is shown in SEQ ID NO: 54; the nucleotide sequence of its Kozak sequence is shown in SEQ ID NO: 1; the amino acid sequence of its leader sequence is shown in SEQ ID NO: 3; its hinge The amino acid sequence of the region is shown in SEQ ID NO: 62; the amino acid sequence of its transmembrane domain is shown in SEQ ID NO: 66; the amino acid sequence of its costimulatory domain is shown in SEQ ID NO: 70; its CD3 ⁇ cell
  • the CAR described in this application may be CAR10H10-1, and the amino acid sequence of LCDR1-3 is shown in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20, respectively; the amino acid sequence of VL is SEQ ID NO: 44; the amino acid sequences of HCDR1-3 are shown in SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 50; VH and VL
  • the amino acid sequence of the connecting peptide is shown in SEQ ID NO: 54; the nucleotide sequence of its Kozak sequence is shown in SEQ ID NO: 1; the amino acid sequence of its leader sequence is shown in SEQ ID NO: 3;
  • the amino acid sequence of the hinge region is shown in SEQ ID NO: 62; the amino acid sequence of its transmembrane domain is shown in SEQ ID NO: 66; the amino acid sequence of its costimulatory domain is shown in SEQ ID NO: 70; its CD3 ⁇ The amino
  • the CAR described in this application may be CAR16F10, and the amino acid sequences of LCDR1-3 are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is SEQ ID NO: 46; the amino acid sequence of HCDR1-3 is shown in SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 52; between VH and VL
  • the amino acid sequence of the connecting peptide is shown in SEQ ID NO: 54; the nucleotide sequence of its Kozak sequence is shown in SEQ ID NO: 1; the amino acid sequence of its leader sequence is shown in SEQ ID NO: 3; its hinge region
  • the amino acid sequence is shown in SEQ ID NO: 62; the amino acid sequence of its transmembrane domain is shown in SEQ ID NO: 66; the amino acid sequence of its costimulatory domain is shown in SEQ ID NO: 70; its CD3 ⁇ cell
  • the present application provides isolated one or more nucleic acid molecules, which can encode the antibodies, antigen-binding fragments or variants described herein, and/or, encode the fusion protein.
  • the isolated nucleic acid molecule encoding the antibody of the present application may comprise the nucleic acid sequence shown in SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59 or a functional variant thereof.
  • the nucleic acid molecules described in this application may be isolated.
  • the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA technology.
  • the present application provides one or more vectors, which may contain one or more nucleic acid molecules described in the present application.
  • the vector may be PXC17.4 or pCDNA3.4.
  • the PXC17.4 or pCDNA3.4 vector may include the nucleic acid sequence shown in SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59 or a functional variant thereof.
  • the vector may also contain other genes, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions.
  • the vector may also contain expression control elements that allow the coding region to be correctly expressed in a suitable host. Such control elements are well known to those skilled in the art.
  • the expression control sequence may include promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation.
  • the expression control sequence is an adjustable element.
  • the specific structure of the expression control sequence may vary according to the function of the species or cell type, but usually contains 5'untranscribed sequences and 5'and 3'untranslated sequences involved in transcription and translation initiation, such as TATA box, Cap sequence, CAAT sequence, etc.
  • the 5' non-transcriptional expression control sequence may comprise a promoter region, and the promoter region may comprise a promoter sequence for transcriptional control of functionally linked nucleic acids.
  • One or more nucleic acid molecules described herein can be operably linked to the expression control element.
  • the vector may include, for example, a plasmid, cosmid, virus, bacteriophage, or other vectors commonly used in, for example, genetic engineering.
  • the present application provides one or more cells, which may comprise one or more nucleic acid molecules described herein or one or more vectors described herein.
  • the cells may be selected from PBMC, CD4, CD8, NK and other cells.
  • each or each cell may contain one or one vector described herein.
  • each or each cell may contain multiple (eg, 2 or more) or multiple (eg, 2 or more) vectors described herein.
  • the vector can be introduced into immune effector cells.
  • the vector described in the present application can be introduced into the cells by methods known in the art.
  • the vector described in this application can be introduced into the cells by methods known in the art, such as electroporation, lipofectamine transfection (lipofectamine 2000, Invitrogen), and the like.
  • electroporation lipofectamine transfection (lipofectamine 2000, Invitrogen), and the like.
  • electrical transduction can be performed by Bio-Rad's electrical transduction tool.
  • transduction can be performed by Gibco's transfection kit.
  • the present application provides a method for preparing the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein described in the present application, the method may include An antigen-binding fragment or variant thereof, and/or the fusion protein described herein under the conditions for expressing the cells described herein may further comprise harvesting the antibody, antigen-binding fragment or variant thereof, and/or , The fusion protein.
  • composition pharmaceutical use
  • the present application provides a pharmaceutical composition, which may comprise the antibody described herein, the antigen-binding fragment or variant thereof, the nucleic acid molecule described herein, the carrier described herein, or the The cells and/or fusion proteins described herein, and optionally a pharmaceutically acceptable adjuvant.
  • the pharmaceutically acceptable adjuvants may include buffers, antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers, amino acids, sugars, chelating agents, counterions, metal complexes and/or nonionic surfaces Active agent, etc.
  • the pharmaceutical composition may be formulated for oral administration, intravenous administration (eg, intravenous injection, IV), intramuscular administration (eg, intramuscular injection, IM), the original in the tumor site Site administration, inhalation, rectal administration, vaginal administration, transdermal administration (eg, subcutaneous injection, IC) or administration via subcutaneous depot.
  • intravenous administration eg, intravenous injection, IV
  • intramuscular administration eg, intramuscular injection, IM
  • the original in the tumor site Site administration inhalation
  • rectal administration vaginal administration
  • transdermal administration eg, subcutaneous injection, IC
  • administration via subcutaneous depot e.g, subcutaneous injection, IC
  • the present application provides the antibody, antigen-binding fragment or variant thereof, and/or the use of the fusion protein in the preparation of a medicament for preventing or treating a disease or disorder, wherein the medicament is used for Treatment of tumors and autoimmune diseases.
  • the present application provides the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein, which treats tumors and autoimmune diseases.
  • the present application provides a method for treating tumors and autoimmune diseases, comprising administering the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein to a patient.
  • the tumor is selected from any one of the group consisting of B-cell subtype non-Hodgkin's malignant lymphoma (NHL), Burkitt's lymphoma, multiple myeloma, pre-B Acute lymphoblastic leukemia and other malignant lung tumors derived from early B-cell precursors, common acute lymphocytic leukemia, T chronic lymphocytic leukemia, hairy cell leukemia, non-acute lymphoblastic leukemia, Fahrenheit macroglobulin blood Disease, prolymphocytic leukemia, plasmacytoma, osteosclerotic myeloma, plasmacytic leukemia, monoclonal gammopathy (MGUS), smoldering multiple myeloma (SMM), chronic multiple myeloma (IMM) ), Hodgkin's malignant lymphoma, gastric cancer, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer,
  • NHL B
  • the present application provides a method for inhibiting the biological activity of CD19 protein, which comprises administration of the antibody described herein, antigen-binding fragment or variant thereof, the nucleic acid molecule described herein, the The carrier, the cell described in this application and/or the fusion protein described in this application.
  • the present application provides the antibody, antigen-binding fragment or variant thereof, the nucleic acid molecule described herein, the vector described herein, the cell described herein, and/or the The application of the fusion protein described above in the preparation of reagents for diagnosis or detection of tumors.
  • the reagent for diagnosing or detecting tumors can specifically recognize CD19 protein and/or cancer cells bearing CD19 protein.
  • the reagents for diagnosing or detecting tumors can be diagnosed in vitro by methods such as enzyme-linked immunoassay, chemiluminescence, and immunoturbidimetry.
  • the detection can be performed by enzyme-linked immunosorbent assay, using the tumor marker CD19 protein as a stationary phase, and competing with the sample to be tested for the antibody described in this application.
  • the reagent for diagnosing or detecting tumors can react with a substrate of horseradish peroxidase to develop a color for diagnosis of tumors.
  • Each mouse was then injected subcutaneously with 1 mL of Ramos cell solution for immunization.
  • the fourth immunization was performed, the immunization was performed with the Ramos cell solution, and 1 mL of Ramos cell solution was injected subcutaneously into each mouse for immunization.
  • the eyeball blood was taken and the serum antibody titer was detected by ELISA.
  • mice that produce antibodies that specifically bind to CD19
  • the sera of the immunized mice were tested by ELISA as described by Fishwild et al. (1996).
  • the mice whose serum antibody dilution reached more than 10 5 after immunization with recombinant CD19 protein in Example 1.2 were taken, and their spleen was removed after being sacrificed by neck removal.
  • the spleen was crushed and separated using a 70 ⁇ m sieve (corning) to obtain a single
  • the B cells and SP2/0 cells were mixed at a ratio of 1:10, and the B cells and SP2/0 cells were fused into hybridoma cells by means of PEG (purchased from Sigma).
  • the fused cells were dispensed into 96-well cell culture plates in an amount of 200 ⁇ L per well, for a total of 30 96-well cell culture plates.
  • the 96-well cell culture plate was cultured in a 5% CO 2 cell incubator (Thermo 150i) at 37°C, and then a fusion cell line secreting highly active antibodies was screened by ELISA as described by Fishwild et al. (1996).
  • the plate was washed 5 times with PBS/Tween, and 100 ⁇ L of goat-anti-human IgG polyclonal antibody conjugated with horseradish peroxidase (HRP) was added to each well and incubated at 37°C for 30 minutes. After washing 5 times with PBS/Tween, 100 ⁇ L of TMB color developing solution (Shandong Zibo Yunqiao Biotechnology Co., Ltd.) was added to each well. After incubation at 37° C.
  • HRP horseradish peroxidase
  • Three anti-CD19 murine antibodies with different affinities and binding epitopes were screened by hybridoma fusion technology and named 25C5-2, 10H10-1 and 16F10 respectively. Sequencing by Sanger high-throughput sequencing technology (see Tsiatis A, C, Norris-Kirby A, Rich R, G, and others.
  • VL-VH connecting peptide between the VL and VH is artificially synthesized, and its nucleotide sequence is shown in SEQ ID NO:53.
  • nucleotide sequences of VL and VH of the three strains of antibodies that can specifically bind to CD19 obtained by sequencing in the previous step are artificially synthesized, and then connected first to construct the CD19 antibody in scFv format.
  • the 25C5-2 antibody first synthesize its VL, whose nucleotide sequence is shown in SEQ ID NO: 41; then synthesize the VL-VH linking peptide, whose nucleotide sequence is shown in SEQ ID NO: 53 Then, its VH is synthesized, and its nucleotide sequence is shown in SEQ ID NO: 47.
  • the nucleotide sequences of VL, VL-VH linking peptide and VL are connected end to end to obtain the complete 25C5-2scFv sequence.
  • the nucleotide sequence is shown in SEQ ID NO: 55.
  • the 16F10 antibody first synthesize its VL, whose nucleotide sequence is shown in SEQ ID NO: 45; then synthesize the VL-VH connecting peptide, whose nucleotide sequence is shown in SEQ ID NO: 53; then Synthesize its VH, and its nucleotide sequence is shown in SEQ ID NO: 51.
  • the nucleotide sequences of VL, VL-VH connecting peptide and VL are connected end to end to obtain the complete 16F10scFv sequence.
  • the nucleotide sequence is shown in SEQ ID NO:59.
  • the scFv gene synthesized in the previous step was amplified by E. coli to extract the plasmid, digested with BamHI and SaiL, and then ligated into the expression vector PXC17.4, etc., electroporation was performed using Bio-Rad's electrical transduction tool, and the expression vector was introduced into CHO The cells are expressed, and then the expression of the antibody is detected.
  • the CD19 antibody prepared in Example 1 was detected by ELISA. Take 100 ⁇ g of CD19 protein (purchased from acro), add 300 ⁇ L of ultrapure water (purified water meter purchased from PALL) to fully dissolve, and obtain a CD19 protein dilution with a concentration of 0.33 ⁇ g/ ⁇ L. A 96-well test plate was coated with 100 ng per well.
  • the antibodies 16F10, 25C5-2, and 10H10-1 prepared in Example 1 were used for detection, and FMC-63 (Merck, selection MAB1794) was used as a positive control (all anti-CD19 positive controls used in all examples of this application were It is FMC-63.
  • FMC-63 Merck, selection MAB1794.
  • scfv nucleotide sequence please refer to CN201180067173.X SEQ ID NO.14, and the amino acid sequence is SEQ ID NO.20), without adding primary antibody or secondary antibody as a negative control.
  • the diluted test plate was incubated at 37°C for 30 minutes.
  • the plate was washed 5 times, 280 ⁇ L each time. After the plate was washed, the plate was gently patted several times to remove the residual washing solution. Then, add the prepared goat anti-human secondary antibody dilution solution (the goat anti-human secondary antibody was purchased from abcam and diluted with PBS at a ratio of 1:10000) according to the amount of 100 ⁇ L per well. After incubating at 37°C for 30 minutes, the plate was washed . After washing the plate, add TMB color developing solution according to 100 ⁇ L of each well, incubate at 37°C for 5 minutes and add 2M sulfuric acid stop solution according to the amount of 50 ⁇ L per well to stop the reaction.
  • TMB color developing solution according to 100 ⁇ L of each well
  • 2M sulfuric acid stop solution according to the amount of 50 ⁇ L per well to stop the reaction.
  • the CD19 antibody was diluted with PBS according to the following gradient.
  • the specific operation is as follows: take the antibodies 16F10, 10H10-1 and 25C5-2 prepared in Example 1 and dilute them to 50 ⁇ g/mL, 10 ⁇ g/mL, 5 ⁇ g/mL, 2.5 ⁇ g/mL and 1.25 ⁇ g/mL respectively. 200 ⁇ L was added to the cell pellet collected by centrifugation to resuspend the cells. After reacting at 4° C. for 1 hour, the cells were collected by centrifugation and washed three times with PBS.
  • FITC-labeled goat anti-mouse antibody Abcam Anti-Mouse IgG H&L (FITC) ab6785
  • PBS dilution 500 ⁇ L of FITC-labeled goat anti-mouse was added to each detection tube Resuspend the cells in the antibody dilution, and add 500 ⁇ L LITC-labeled goat anti-mouse antibody dilution to the FITC-labeled goat anti-mouse antibody control group.
  • wash the cells three times with PBS as described above Finally, resuspend and wash the centrifuged cells with 200 ⁇ L PBS for flow cytometry.
  • the flow detection voltage is set according to the following steps: After a sufficient amount of sheath liquid is filled in the flow sheath liquid barrel, the flow cytometer (BD verse) is preheated for 20 minutes, the flow detection software is opened, and the FSC/ adhesion to the SSC, FSC and SSC detection Videos in FIG appropriate detection gate, the amount of the detection cell 10 set the detection threshold of 4, FSC-H and then draw a second detector detecting FIG FIGS-a FSC, defined
  • the detection cells on the second detection chart come from P1 gate, and set the appropriate P2 gate on the second detection chart, set the third detection chart COUNT and FITC-A, define the detection data of the third picture from P2 gate After the related test chart is drawn, set the detection voltage with the control NALM-6 cells so that the NALM-6 cells are displayed at the center of the first test chart.
  • start Test NALM-6 cells collect data and set up a control group, save the test voltage and related parameters, and then start the test sample test, and record the related data.
  • the results of 16F10, 10H10-1, 25C5-2 antibody concentration of 5 ⁇ g/mL and FMC63 concentration of 0.025 ⁇ g/mL are plotted. The results are shown in FIG. 2.
  • Marker used in electrophoresis was purchased from full-type gold, catalog number: DM201, lot: K51027, and 5 ⁇ L of each sample was added.
  • Use concentrated gel (5% concentrated gel, 2mL, purified water 1.4mL, 30% Acr-Bis 0.33mL, 1M pH8.8 Tris 0.25mL, 12% SDS (sodium dodecyl sulfonate) 0.02mL, 10% Ammonium persulfate 0.02ml, TEMED (tetramethyldiethylamine) 0.002mL) was concentrated, the voltage was 100V during concentration; use separation gel (10% concentrated gel, 5mL, purified water 1.3mL, 30% Acr-Bis 1.7mL, 1M pH8.8Tris 1.9mL, 12% SDS (sodium dodecyl sulfonate) 0.05mL, 10% ammonium persulfate 0.05mL, TEMED (tetramethyldie
  • the film transfer was performed at a constant voltage of 100V, and the film transfer time was 45 minutes.
  • the polyvinylidene fluoride (PVDF) membrane was placed in a 5% skimmed milk powder solution (PBST solution configuration) for 1 hour, washed 3 times with PBST solution, and washed slowly on a side swing shaker for about 5 minutes each time.
  • the CD19 antibodies 10H10-1, 25C5-1 and the positive control FMC-63 obtained in Example 1 were diluted with PBST to a concentration of 20 ⁇ g/mL and reacted with 5% skim milk-blocked PVDF membrane for 1 hour at room temperature. Then wash with PBST three times, each time on the side shaker and shake slowly for about 5 minutes.
  • NALM-6 cells Take the same NALM-6 cells as in Example 3, collect NALM-6 cells into a 15ml centrifuge tube, centrifuge at 400g for 5 minutes to collect the cells, discard the supernatant, and use the same volume as the discarded supernatant
  • the cells collected by centrifugation were resuspended in PBS buffer solution, and after 3 repetitions, the cells were resuspended with 10 mL of PBS buffer solution.
  • the washed cell suspension was then divided into flow detection tubes, 1 mL per tube. Reserve a tube as a negative control.
  • CD19 antibodies 10H10-1 and 25C5-2 Dilute the CD19 antibodies 10H10-1 and 25C5-2 to be tested to a concentration of 200 ⁇ g/mL in PBS, and then dilute them at the ratios of 1:20, 1:80, 1:320, 1:1280, and 1:5120 respectively.
  • the cells were collected by centrifugation at 4°C for 5 minutes at a speed of 400g, and 1mL of PBS buffer solution pre-cooled to 4°C was added.
  • the flow detection voltage is set according to the following steps: After a sufficient amount of sheath liquid is filled in the flow sheath liquid barrel, the flow cytometer (BD verse) is preheated for 20 minutes, the flow detection software is opened, and the FSC/ adhesion to the SSC, FSC and SSC detection Videos in FIG appropriate detection gate, the amount of the detection cell 10 set the detection threshold of 4, FSC-H and then draw a second detector detecting FIG FIGS-a FSC, defined
  • the detection cells of the second detection chart come from P1 gate, and set the appropriate P2 gate on the second detection chart, set the third detection chart COUNT and FITC-A, define the detection data of the third picture from P2 gate, After the relevant detection chart is drawn, set the detection voltage with the control NALM-6 cells so that the NALM-6 cells are displayed in the center of the first detection chart. After the FITC-A detection signal is between 10-10 2 , start to detect NALM -6 cells, collect data to set up a control group, save the test voltage and related parameters,
  • the obtained anti-CD19scfv and different functional regions form a CAR structure and then the CAR structure is obtained by gene synthesis (the schematic diagram of the CAR structure is shown in Figure 5)
  • nucleotide sequence of the leader is shown in SEQ ID NO. 2; the nucleotide sequence of the hinge region (Hinge) is shown in SEQ ID NO. 61, and the nucleotide sequence of the transmembrane structure (TM) is shown in SEQ ID NO.65, 4-1BB nucleotide sequence is shown in SEQ ID NO.69, OX40 nucleotide sequence is shown in SEQ ID NO.71, CD3zeta nucleotide sequence is shown in SEQ ID NO.73 As shown.
  • the anti-CD19scfv obtained through screening in this application was constructed with 10H10-1 (SEQ ID NO.57) and 25C5-2 (SEQ ID NO.55) as examples, and the positive drug CAR-T (anti-CD19scfv (FMC-63 (Merck))
  • Synthetic genes are amplified by the large intestine, and plasmids are extracted. They are digested with BamHI and SaiL and then ligated into expression vectors. The plasmids are amplified by stabl3 to prepare plasmids for constructing CAR-T cells
  • the constructed anti-CD19CAR-T expression vector was prepared according to the amount of 3.3 ⁇ g corresponding to 4 ⁇ 10 6 T cells.
  • the electrotransformation conditions were followed to collect T cells after electroporation according to the program set together, and the CAR-T cell positive rate and CAR- were detected in 24 hours. T cells kill vitality.
  • NALM-6 cells were washed 4 times with washing solution (1 ⁇ PBS+20 mM Hepes). After the final wash, resuspend the cells in complete medium and adjust the cell density to 8 ⁇ 10 4 cell/mL.
  • target cells are resuspended, an appropriate amount of cell suspension is immediately centrifuged, and the supernatant is taken as a background test well.
  • the fluorescence value was measured by HTRF method (excitation light 340 nm, emission light 615 nm).
  • Cell killing rate (%) (Test well reading-Spontaneous release well reading) / (Maximum release well reading-Spontaneous release well reading) ⁇ 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种特异性结合CD19的抗体或其抗原结合片段，其以3.5μg/mL或更低的IC50值与CD19蛋白相结合，以及该抗体或其抗原结合片段在制备药物中的用途。

Description

CD19抗体及其应用 技术领域
本申请涉及生物医药领域，具体涉及一种与CD19蛋白特异性结合的抗体或其抗原结合片段。
背景技术
B淋巴细胞抗原CD19，也称为CD19分子(分化簇19)。在正常的淋巴组织中，CD19表达于生发中心的B细胞和滤泡树突状细胞、套细胞、滤泡间T细胞区的树突状大细胞。CD19在人体B细胞中主要起到两个作用，一是充当衔接蛋白以将细胞质信号蛋白募集到膜上，二是在CD19/CD21复合物内起作用以降低B细胞受体信号传导途径的阈值。CD19蛋白是B淋巴细胞表面稳定存在的一种靶蛋白，存在于B细胞成熟的各个阶段，大多数血液瘤相关的肿瘤(B-ALL/CLL/B-NHL等)都高表达CD19，而在造血干细胞、其他正常细胞中不表达，因此CD19成为治疗血液瘤相关肿瘤的重要靶点。
然而，目前已研发的CD19抗体特异性较低，且对肿瘤的抑制能力有限，因此亟待开发新的抗CD19药物以用于新药研发。
发明内容
本申请提供了一种特异性结合CD19的抗体或其抗原结合片段及其应用。本申请还提供了包含所述抗体或其抗原结合片段融合蛋白，编码所述抗体或其抗原结合蛋白的核酸分子，包含所述核酸分子的载体，包含所述载体或所述核酸分子的细胞等。本申请提供的抗CD19抗体具有下列性质中的一种或多种：1)能特异性结合CD19蛋白；2)针对CD19蛋白不同表位拥有不同亲和特征；3)具有良好的靶向杀伤效果；4)具有较高稳定性；5)具有较高纯度；6)能够用于治疗癌症。
一方面，本申请提供了一种抗体、其抗原结合片段或变体，其以3.5μg/ml或更低的IC 50值与CD19蛋白相结合。
在某些实施方式中，所述抗体选自下组中任一项：单克隆抗体、单链抗体、嵌合抗体、鼠源抗体和人源化抗体。
在某些实施方式中，所述抗原结合片段选自：Fab、Fab’、F(ab)2、F(ab’)2、Fv和scFv。
在某些实施方式中，所述变体选自下组：1)在所述抗体或所述其抗原结合片段中经过取 代、缺失或添加一个或多个氨基酸的蛋白质或多肽；和2)与所述抗体或所述其抗原结合片段具有90％以上序列同源性的蛋白质或多肽。
另一方面，本申请提供了一种抗体、其抗原结合片段或变体，所述抗体、其抗原结合片段或变体与参比抗体竞争结合所述CD19蛋白，其中所述参比抗体包含轻链可变区和重链可变区，所述参比抗体的轻链可变区包含LCDR1-3，所述LCDR1的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:4和SEQ ID NO:18；所述LCDR2的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:5和SEQ ID NO:19；以及所述LCDR3的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:6和SEQ ID NO:20；且所述参比抗体的重链可变区包含HCDR1-3，所述HCDR1的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:7、SEQ ID NO:21和SEQ ID NO:32；所述HCDR2的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:8、SEQ ID NO:22和SEQ ID NO:33；以及所述HCDR3的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:9、SEQ ID NO:23和SEQ ID NO:34。
在某些实施方式中，所述参比抗体的轻链可变区的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:42、SEQ ID NO:44和SEQ ID NO:46，且所述参比抗体的重链可变区的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:48、SEQ ID NO:50和SEQ ID NO:52。
在某些实施方式中，所述抗体以3.5μg/ml或更低的IC 50值与CD19蛋白相结合。
在某些实施方式中，所述抗体选自下组中任一项：单克隆抗体、单链抗体、嵌合抗体、鼠源抗体和人源化抗体。
在某些实施方式中，所述抗原结合片段选自：Fab、Fab’、F(ab)2、F(ab’)2、Fv和scFv。
在某些实施方式中，所述变体选自下组：1)在所述抗体或所述其抗原结合片段中经过取代、缺失或添加一个或多个氨基酸的蛋白质或多肽；和2)与所述抗体或所述其抗原结合片段具有90％以上序列同源性的蛋白质或多肽。
另一方面，本申请提供了一种抗体、其抗原结合片段或变体，所述抗体、其抗原结合片段或变体包含LCDR1，且所述LCDR1包含选自下组任一项所示的氨基酸序列：SEQ ID NO:4和SEQ ID NO:18。在某些实施方式中，其包含LCDR2，且所述LCDR2包含选自下组任一项所示的氨基酸序列：SEQ ID NO:5和SEQ ID NO:19。在某些实施方式中，其包含LCDR3，且所述LCDR3包含选自下组任一项所示的氨基酸序列：SEQ ID NO:6和SEQ ID NO:20。在某些实施方式中，其包含轻链可变区VL，且所述轻链可变区VL包含选自下组任一项所示的 氨基酸序列：SEQ ID NO:42、SEQ ID NO:44和SEQ ID NO:46。
在某些实施方式中，其包含HCDR1，且所述HCDR1包含选自下组任一项所示的氨基酸序列：SEQ ID NO:7、SEQ ID NO:21和SEQ ID NO:32。在某些实施方式中，其包含HCDR2，且所述HCDR2包含选自下组任一项所示的氨基酸序列：SEQ ID NO:8、SEQ ID NO:22和SEQ ID NO:33。在某些实施方式中，其包含HCDR3，且所述HCDR3包含选自下组任一项所示的氨基酸序列：SEQ ID NO:9和SEQ ID NO:23和SEQ ID NO:34。在某些实施方式中，其包含重链可变区VH，且所述重链可变区VH包含选自下组任一项所示的氨基酸序列：SEQ ID NO:48、SEQ ID NO:50和SEQ ID NO:52。
在某些实施方式中，所述抗体或其抗原结合片段为scFv。在某些实施方式中，所述scFv包含选自下组任一项所示的氨基酸序列：SEQ ID NO:56、SEQ ID NO:58和SEQ ID NO:60。
在某些实施方式中，所述抗体以3.5μg/ml或更低的IC 50值与CD19蛋白相结合。
在某些实施方式中，所述抗体选自下组中任一项：单克隆抗体、单链抗体、嵌合抗体、鼠源抗体和人源化抗体。
在某些实施方式中，所述抗原结合片段选自：Fab、Fab’、F(ab)2、F(ab’)2、Fv和scFv。
在某些实施方式中，所述变体选自下组：1)在所述抗体或所述其抗原结合片段中经过取代、缺失或添加一个或多个氨基酸的蛋白质或多肽；和2)与所述抗体或所述其抗原结合片段具有90％以上序列同源性的蛋白质或多肽。
在某些实施方式中，所述CD19蛋白为小鼠CD19蛋白。
另一方面，本申请提供了一种融合蛋白，其包含本申请所述的抗体、其抗原结合片段或变体。在某些实施方式中，所述融合蛋白为嵌合抗原受体。
在某些实施方式中，所述嵌合抗原受体包含胞外铰链区、跨膜结构域、共刺激结构域和CD3ζ胞内信号转导结构域。
在某些实施方式中，所述胞外铰链区选自CD8铰链或IgG4铰链。
在某些实施方式中，所述跨膜结构域选自T细胞受体的α，β或ζ链、CD28、CD3e、CD45、CD4、CD5、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137和CD154。在某些实施方式中，所述跨膜结构域选自CD8-1或CD8-2。
在某些实施方式中，所述共刺激结构域选自CD27、CD28、4-1BB、OX40或ICOS。
在某些实施方式中，所述的嵌合抗原受体，所述胞外铰链区选自CD8铰链或IgG4铰链；所述跨膜结构域选自CD8-1或CD8-2；所述共刺激结构域选自4-1BB或OX40。
在某些实施方式中，所述的嵌合抗原受体，所述CD8-1跨膜的N端与所述CD8铰链的C 端相连，所述CD8-1跨膜的C端与所述4-1BB的N端相连，所述4-1BB的C端与所述OX40的N端相连，所述OX40的C端与所述CD3ζ的N端相连。
在某些实施方式中，所述的嵌合抗原受体，所述CD8-2跨膜的N端与所述IgG4铰链的C端相连，所述CD8-2跨膜的C端与所述4-1BB的N端相连，所述4-1BB的C端与所述OX40的N端相连，所述OX40的C端与所述CD3ζ的N端相连。
另一方面，本申请提供了分离的一种或多种核酸分子，其编码本申请所述的抗体、其抗原结合片段或变体，和/或，其编码本申请所述的融合蛋白。
另一方面，本申请提供了一种或多种载体，其包含本申请所述的一种或多种核酸分子。
另一方面，本申请提供了一种或多种细胞，其包含本申请所述的一种或多种核酸分子或本申请所述的一种或多种载体。
另一方面，本申请提供了制备本申请所述的抗体、其抗原结合片段或变体，和/或，本申请所述的融合蛋白的方法，所述方法包括在使得本申请所述抗体、其抗原结合片段或变体，和/或，本申请所述的融合蛋白表达的条件下，培养本申请所述的细胞。在某些实施方式中，本申请所述方法包含收获所述抗体、其抗原结合片段或变体，和/或，所述的融合蛋白。
另一方面，本申请提供了一种药物组合物，其包含本申请所述的抗体、其抗原结合片段或变体、本申请所述的核酸分子、本申请所述的载体、本申请所述的细胞和/或本申请所述的融合蛋白，以及任选地药学上可接受的佐剂。
另一方面，本申请提供了所述的抗体、其抗原结合片段或变体，和/或，所述的融合蛋白在制备预防或治疗疾病或病症的药物中的用途。
在某些实施方式中，所述疾病或病症选自下组中的任一项：肿瘤和自体免疫疾病。
在某些实施方式中，所述肿瘤选自下组中的任一项：B细胞亚型非霍奇金氏恶性淋巴瘤(NHL)、伯基特氏淋巴瘤、多发性骨髓瘤、前B急性淋巴母细胞性白血病及其他来源于早期B细胞前体的恶性肺瘤、普通急性淋巴细胞白血病、T慢性淋巴细胞性白血病、毛细胞白血病、非急性淋巴母细胞性白血病、华氏巨球蛋白血症、前淋巴细胞性白血病、浆细胞瘤、骨硬化骨髓瘤、浆细胞性白血病、单克隆丙种球蛋白病(MGUS)、郁积性多发性骨髓瘤(SMM)、缓慢性多发性骨髓瘤(IMM)、霍奇金氏恶性淋巴瘤、胃癌、肝癌、白血病、肾脏肿瘤、肺癌、小肠癌、骨癌、前列腺癌、结直肠癌、乳腺癌、大肠癌、前列腺癌、宫颈癌、肾上腺肿瘤和膀胱肿瘤。
在某些实施方式中，所述自体免疫疾病选自下组中的任一项：类风湿性关节炎、多发性硬化症和CD19 +白血病。
另一方面，本申请提供了一种抑制CD19蛋白生物学活性的方法，其包括施用本申请所 述的抗体、其抗原结合片段或变体、所述的核酸分子、所述的载体、所述的细胞和/或所述的融合蛋白。
另一方面，本申请提供了本申请所述的抗体、其抗原结合片段或变体、所述的核酸分子、所述的载体、所述的细胞和/或所述的融合蛋白在制备诊断或检测肿瘤的试剂中的应用。
本领域技术人员能够从下文的详细描述中容易地洞察到本申请的其它方面和优势。下文的详细描述中仅显示和描述了本申请的示例性实施方式。如本领域技术人员将认识到的，本申请的内容使得本领域技术人员能够对所公开的具体实施方式进行改动而不脱离本申请所涉及发明的精神和范围。相应地，本申请的附图和说明书中的描述仅仅是示例性的，而非为限制性的。
附图说明
本申请所涉及的发明的具体特征如所附权利要求书所显示。通过参考下文中详细描述的示例性实施方式和附图能够更好地理解本申请所涉及发明的特点和优势。对附图简要说明书如下：
图1显示的是本申请所述的CD19抗体ELISA活性检测结果。
图2显示的是本申请所述的CD19抗体流式活性检测结果。
图3显示的是本申请所述的CD19抗体蛋白印迹法检测结果。
图4显示的是不同浓度本申请所述的CD19抗体流式活性检测结果。
图5显示的是本申请实施例中构建的CAR结构示意图。
图6显示的是anti-CD19CAR-T阳性率检测结果。
具体实施方式
以下由特定的具体实施例说明本申请发明的实施方式，熟悉此技术的人士可由本说明书所公开的内容容易地了解本申请发明的其他优点及效果。本申请提供了一种可以特异性结合CD19蛋白的抗体，其可以能特异性结合CD19蛋白并且针对CD19不同表位拥有不同亲和特征。所述CD19抗体具有良好的靶向杀伤效果、较高的稳定性、较高的纯度。所述CD19抗体能够用于治疗癌症。
以下对本发明做进一步描述：在本发明中，除非另有说明，否则本申请中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且，本申请中所用的蛋白质和核酸化学、分子生物学、细胞和组织培养、微生物学、免疫学相关术语和实验室操作步骤均为相应领域内广泛使用的术语和常规步骤。同时，为了更好地理解本发明，下面提供相关术语的定义和 解释。
在本申请中，术语“抗体”通常是指一种能够特异性识别和/或中和特定抗原的多肽分子。例如，抗体可包含通过二硫键相互连接的至少两条重(H)链和两条轻(L)链组成的免疫球蛋白，并且包括任何包含其抗原结合部分的分子。术语“抗体”包括单克隆抗体、抗体片段或抗体衍生物，包括但不限于人抗体、人源化抗体、嵌合抗体、单域抗体(例如，dAb)，单链抗体(例如，scFv)，以及与抗原结合的抗体片段(例如，Fab、Fab’和(Fab)2片段)。在本申请中，术语“单克隆抗体”(monoclonal antibody，mAb)通常是指仅由一种类型的免疫细胞制造出来的抗体，也可以由制造这种抗体的免疫细胞与癌细胞融合后产生的杂交瘤细胞产生。在本申请中，术语“单链抗体”(single chain antibody fragment，scFv)通常是指由抗体重链可变区和轻链可变区通过连接子连接而成的抗体。scFv可以较好地保留其对抗原的亲和活力，并且具有分子量小、穿透力强和抗原性弱等特点。在本申请中，术语“人源化抗体”通常是指鼠源单克隆抗体以基因克隆及DNA重组技术改造，重新表达的抗体，其大部分氨基酸序列为人源序列取代，基本保留亲本鼠单克隆抗体的亲和力和特异性，又降低了其异源性，有利应用于人体。在本申请中，术语“嵌合抗体”通常是指由鼠源性抗体的V区基因与人抗体的C区基因拼接而成的抗体，因其减少了鼠源的成分，从而减低了鼠源性抗体引起的不良反映，并有助于提高疗效。在本申请中，术语“鼠源抗体”通常是指将来源于免疫接种过的小鼠的B细胞与骨髓瘤细胞融合，继而筛选出既能无线增殖又能分泌抗体的鼠杂交融合细胞，进而筛选、制备抗体以及纯化。术语“抗体”还包括抗体的所有重组体形式，例如在原核细胞中表达的抗体以及本申请所述的任何与抗原结合的抗体片段及其衍生物。每条重链可由重链可变区(VH)和重链恒定区构成。每条轻链可由轻链可变区(VL)和轻链恒定区构成。VH和VL区可进一步被区分为称为互补决定区(CDR)的高变区，它们散布在称为构架区(FR)的更保守的区域中。每个VH和VL可由三个CDR和四个FR区构成，它们从氨基端至羧基端可按以下顺序排列：FR1、CDR1、FR2、CDR2、FR3、CDR3和FR4。重链和轻链的可变区含有与抗原相互作用的结合结构域。抗体的恒定区可介导该免疫球蛋白与宿主组织或因子的结合，所述宿主组织或因子包括免疫系统的多种细胞(例如，效应细胞)和经典补体系统的第一成分(Clq)。
在本申请中，术语“抗体结合片段”通常是指抗体中发挥特异性结合抗原功能的一个或多个片段。抗体的抗原结合功能可通过抗体的全长片段来实现。抗体的抗原结合功能也可通过以下的片段来实现：(1)Fab片段，即由VL、VH、CL和CH结构域组成的一价片段；(2)F(ab’)2片段，包含通过铰链区处的二硫键连接的两个Fab片段的二价片段；(3)由VH和CH结构域组成的Fd片段；(4)由抗体单臂的VL和VH结构域组成的Fv片段；(5) 由VH结构域组成的dAb片段(Ward等，(1989)Nature 341：544-546)；(6)分离的互补决定区(CDR)和(7)可任选地通过接头连接的两个或以上分离的CDR的组合。此外，还可包括由VL和VH配对形成的一价单链分子Fv(scFv)(参见Bird等(1988)Science 242：423-426；以及Huston等(1988)Proc.Natl.Acad.Sci.85：5879-5883)。所述“抗原结合部分”还可包括免疫球蛋白融合蛋白，所述融合蛋白包含选自以下的结合结构域：(1)与免疫球蛋白铰链区多肽融合的结合结构域多肽；(2)与铰链区融合的免疫球蛋白重链CH2恒定区；和(3)与CH2恒定区融合的免疫球蛋白重链CH3恒定区。本申请提供的特异性结合CD19蛋白的抗体，其中所述抗体或其抗原结合片段选自由下述组成的组：Fab、scFv、Fab’、F(ab)2、F(ab’)2和dAb。
在本申请中，术语“CD19蛋白”通常是指主要表达于早期的B细胞的、95kDa左右的B细胞系特有的跨膜糖蛋白。CD19蛋白在正常及恶性B淋巴细胞中均有表达，被视为B细胞发育过程中最为可靠的表面标记物。在本申请中，所述CD19蛋白可以为人CD19蛋白。例如，本申请所述表达的人CD19蛋白可以包含如NCBI中登录号AAB60697所示的氨基酸序列。在某些实施方式中，所述CD19蛋白可为CD19重组蛋白，所述重组蛋白可为CD19蛋白的胞外区。例如，CD19重组蛋白可为abcam的ab234966，氨基酸序列编号第20位至291位的蛋白。
在本申请中，术语“融合蛋白”(fusion proteins)又称嵌合蛋白(chimeric proteins)，通常是指通过DNA重组技术得到的两个基因重组后的表达产物。融合蛋白技术是为了获得大量标准融合蛋白而进行的由目的性的基因融合和蛋白表达方法。利用融合蛋白技术，可构建和表达具有多种功能的新型目的蛋白。所述融合基因的翻译产生具有衍生子每种原始蛋白质的功能特性的单个或多个多肽。通过重组DNA技术人工产生重组的融合蛋白可用于生物研究或治疗。所述嵌合或嵌合体通常表示具有不同功能或物理化学特征的多肽制成的融合蛋白。融合蛋白可包括将抗体的抗原结合区scFv、CD3ζ链或胞内部分融合形成的嵌合抗原受体，其可包括肿瘤相关抗原结合区、胞外铰链区、跨膜区等结构域，所述肿瘤相关抗原结合区可来源于抗体的抗原结合区，例如scFv。
在本申请中，术语“嵌合抗原受体”(chimeric antigen receptor，CAR)是单链抗体的可变区和T细胞信号分子的融合蛋白。它使T细胞可以通过非MHC限制性的方式识别特异性抗原，发挥杀伤作用。在本申请中，术语“单链抗体”可以是由所述重链可变区和所述轻链可变区通过连接肽连接而成的抗体。CAR是嵌合抗原受体T细胞(CAR-T)的核心部件，其可包括CD19结合结构域、跨膜结构域、共刺激结构域和胞内信号转导结构域。
在本申请中，术语“跨膜结构域”(transmembrane domain)通常是指CAR中穿过细胞 膜的结构域，其与细胞内信号转导结构域相连接，起着传递信号的作用。
在本申请中，术语“共刺激结构域”通常是指可以提供免疫共刺激分子的胞内结构域，所述共刺激分子为淋巴细胞对抗原的有效应答所需要的细胞表面分子。
在本申请中，术语“胞内信号传导结构域”通常是指CAR位于细胞内信号传导的组分，其包含信号传导结构域和特异性结合所述受体组分的结构域，例如：其可选自CD3ζ胞内域，CD28胞内域，4-1BB胞内域和OX40胞内域。
与抗体相关的术语“变体”在本申请中指，包含已经通过至少1个，例如1-30，或1-20或1-10个，例如1或2或3或4或5个氨基酸取代、缺失和/或插入而具有氨基酸改变的目标抗体区域(例如重链可变区或轻链可变区或重链CDR区或轻链CDR区)的抗体，其中变体基本上保持改变之前的抗体分子的生物学特性。在一方面，本申请涵盖在本申请中所述的任何抗体的变体。在某些实施方式中，抗体变体保持改变前抗体的至少60％，70％，80％，90％，或100％的生物学活性(例如抗原结合能力)。在某些实施方式中，所述改变不会导致抗体变体丧失对抗原的结合，但任选地可以赋予诸如提高的抗原亲和力和不同的效应子功能等性质。可以理解的，抗体的重链可变区或轻链可变区、或各CDR区可以单独改变或组合改变。在某些实施方案中，在一个或多个或全部三个重链CDR中的氨基酸改变不超过1个、2个、3个、4个、5个、6个、7个、8个、9个或10个。在某些实施方式中，所述氨基酸改变可以为氨基酸取代，例如可以为保守取代。在某些实施方式中，抗体变体与亲本抗体在目的抗体序列区域上具有至少80％、85％、90％或95％或99％或更高的氨基酸同一性。
在本申请中，术语“分离的”通常是指抗体是已经与它的天然环境中的组分分离的抗体。在某些实施方式中，将抗体纯化至大于95％或99％纯度，所述纯度通过例如电泳(例如，SDS-PAGE、等电聚焦(IEF)、毛细管电泳)或色谱(例如，离子交换或反相HPLC)确定。关于评价抗体纯度的方法的综述可参见Flatman，S.等，J.Chrom.B 848(2007)79-87。
在本申请中，术语“核酸分子”通常是指从其天然环境中分离的或人工合成的任何长度的分离形式的核苷酸、脱氧核糖核苷酸或核糖核苷酸或其类似物。本申请所述的核酸分子可以为分离的。例如，其可以是通过以下方法产生或合成的：(i)在体外扩增的，例如通过聚合酶链式反应(PCR)扩增产生的，(ii)通过克隆重组产生的，(iii)纯化的，例如通过酶切和凝胶电泳分级分离，或者(iv)合成的，例如通过化学合成。在某些实施方式中，所述分离的核酸是通过重组DNA技术制备的核酸分子。在本申请中，可以通过本领域已知的多种方法来制备编码所述抗体或其抗原结合片段的核酸，这些方法包括但不限于，采用限制性片段操作或采用合成性寡核苷酸的重叠延伸PCR，具体操作可参见Sambrook等人，Molecular Cloning,A Laboratory Manual，Cold Spring Harbor Laboratory Press，Cold Spring Harbor,N.Y.， 1989；和Ausube等人Current Protocols in Molecular Biology,Greene Publishing and Wiley-Interscience,New York N.Y.,1993。
在本申请中，术语“载体”通常是指能够在合适的宿主中自我复制的核酸分子，用以将插入的核酸分子转移到宿主细胞中和/或宿主细胞之间。所述载体可包括主要用于将DNA或RNA插入细胞中的载体、主要用于复制DNA或RNA的载体，以及主要用于DNA或RNA的转录和/或翻译的表达的载体。所述载体还包括具有多种上述功能的载体。所述载体可以是当引入合适的宿主细胞时能够转录并翻译成多肽的多核苷酸。通常，通过培养包含所述载体的合适的宿主细胞，所述载体可以产生期望的表达产物。在本申请中，所述载体中可包含一种或多种所述核酸分子。此外，所述载体中还可包含其他基因，例如允许在适当的宿主细胞中和在适当的条件下选择该载体的标记基因。此外，所述载体还可包含允许编码区在适当宿主中正确表达的表达控制元件。这样的控制元件为本领域技术人员所熟知的，例如，可包括启动子、核糖体结合位点、增强子和调节基因转录或mRNA翻译的其他控制元件等。在某些实施方式中，所述表达控制序列为可调的元件。所述表达控制序列的具体结构可根据物种或细胞类型的功能而变化，但通常包含分别参与转录和翻译起始的5’非转录序列和5’及3’非翻译序列，例如TATA盒、加帽序列、CAAT序列等。例如，5’非转录表达控制序列可包含启动子区，启动子区可包含用于转录控制功能性连接核酸的启动子序列。
在本申请中，术语“细胞”通常是指可以表达本申请所述的抗体、其抗原结合片段或变体，可以或已经含有包括本申请所述的核酸分子的质粒或载体的个体细胞、细胞系或细胞培养物。所述细胞可以是原核细胞(例如大肠杆菌)，也可以是真核细胞(例如酵母细胞，COS细胞，中国仓鼠卵巢(CHO)细胞，HeLa细胞，HEK293细胞，COS-1细胞，NS0细胞或骨髓瘤细胞)。在某些实施方式中，所述细胞可以为免疫细胞。例如，浆细胞、细胞毒性T细胞、NK细胞、APSC多能细胞、肥大细胞、Ramos细胞、NALM-6细胞。
在本申请中，术语“药学上可接受的佐剂”通常是指药学可接受的制剂载体、溶液或加强制剂特性的添加剂。此类添加剂是所属领域技术人员熟知的。
在本申请中，术语“癌症”通常是指或描述哺乳动物的生理状况，其典型特征在于细胞增殖或存活失调。在本申请中，被称为癌症的过度增殖性疾病包括但不限于实体瘤，例如发生在乳腺、呼吸道、脑、生殖器官、消化道、尿道、眼、肝脏、皮肤、头颈、甲状腺、甲状旁腺的癌症，以及它们的远端转移。这类疾病还包括淋巴瘤、肉瘤和白血病。乳腺癌的实例包括但不限于浸润性导管癌、浸润性小叶癌、乳腺导管原位癌和乳腺小叶原位癌。呼吸道癌症的实例包括但不限于小细胞肺癌和非小细胞肺癌，以及支气管腺瘤和胸膜肺母细胞瘤。脑癌的实例包括但不限于脑干和下丘脑角质瘤、小脑和大脑星状细胞瘤、髓母细胞瘤、室管膜 瘤，以及神经外胚层和松果体肿瘤。男性生殖器肿瘤包括但不限于前列腺和睾丸癌。女性生殖器肿瘤包括但不限于子宫内膜癌、宫颈癌、卵巢癌、阴道癌和外阴癌，以及子宫瘤。消化道肿瘤包括但不限于肛门、结肠、结肠直肠、食管、胆囊、胃、胰腺、直肠、小肠和唾液腺癌。尿道肿瘤包括但不限于膀胱、阴茎、肾、肾盂、输尿管和尿道癌。眼癌包括但不限于眼球内黑素瘤和视网膜母细胞瘤。肝癌的实例包括但不限于肝细胞癌(有或没有纤维板层变异的肝细胞瘤)、胆管癌(肝内胆管癌)和混合型肝细胞胆管细胞癌。皮肤癌包括但不限于鳞状细胞癌、卡波西(Kaposi’s)肉瘤、恶性黑素瘤、Merkel细胞皮肤癌和非黑素瘤型皮肤癌。头颈癌包括但不限于喉/下咽/鼻咽/口咽癌，和嘴唇和口腔癌。淋巴癌包括但不限于AIDS相关的淋巴癌、非霍奇金淋巴癌、皮肤T细胞淋巴癌、霍奇金氏病，以及中枢神经系统淋巴癌。肉瘤包括但不限于软组织肉瘤、骨肉瘤、恶性纤维组织细胞瘤、淋巴肉瘤和横纹肌肉瘤。白血病包括但不限于急性髓样白血病、急性淋巴细胞白血病、慢性淋巴细胞白血病、慢性粒细胞白血病和毛细胞白血病。
在本申请中，术语“自体免疫疾病”通常是指自身免疫性疾病是指机体对自身抗原发生免疫反应而导致自身组织损害所引起的疾病。免疫系统防御机体免受外来的或危险的物质侵袭(识别)，这些物质包括微生物、寄生虫、恶性肿瘤细胞以及移植的器官和组织。正常情况下，免疫系统仅对外来或者危险的物质有反应，而不会对自身组织的抗原出现反应。然而，有时候会出现免疫功能异常，把自身的组织当作外来的，而产生抗体(被称为自身抗体)或免疫细胞攻击自身的细胞或组织。这种反应被称为自身免疫反应。它导致炎症和组织损伤。这种反应可能会导致自身免疫病，但有些人产生的自身抗体量非常少而不发生自身免疫病。常见的自身免疫病包括类风湿性关节炎、多发性硬化症和CD19 +白血病。认为属于自身免疫性的额外疾病包括阿狄森病、多肌炎、
Figure PCTCN2019122486-appb-000001
综合征、进行性全身性硬化症、多个肾小球肾炎病例(肾脏炎症)和一些不育病例。
术语“和/或”应理解为意指可选项中的任一项或可选项的两项。
在本申请中，术语“约”通常是指在指定数值以上或以下0.5％-10％的范围内变动，例如在指定数值以上或以下0.5％、1％、1.5％、2％、2.5％、3％、3.5％、4％、4.5％、5％、5.5％、6％、6.5％、7％、7.5％、8％、8.5％、9％、9.5％、或10％的范围内变动。
在本申请中，术语“包括”通常是指包含、总括、含有或包涵的含义。在某些情况下，也表示“为”、“由……组成”的含义。
抗体或其抗原结合片段
本申请提供了一种抗体、其抗原结合片段或变体，其可以3.5μg/mL或更低(例如，3.5μg/ml或更低，3.4μg/mL或更低，3.3μg/mL或更低，3.2μg/mL或更低，3.15μg/mL或更低，3.1μg/ml 或更低，3.0μg/mL或更低，2.9μg/mL或更低，2.8μg/mL或更低，2.5μg/mL或更低或2.1μg/mL或更低)的IC 50值与CD19蛋白相结合。例如，所述IC 50值通过ELISA法测定，所述IC 50值可以为3.12μg/mL或更低。
在本申请中，所述抗体、其抗原结合片段或变体，其可以5μg/mL或更低(例如，5μg/mL或更低，4.5μg/mL或更低，4μg/mL或更低，3.5μg/mL或更低，3μg/mL或更低，2.5μg/mL或更低，2μg/mL或更低，1.5μg/mL或更低，1μg/mL或更低)的IC 50值与CD19蛋白相结合。例如，所述IC 50值通过流式细胞法测定，所述IC 50值可以为5μg/mL或更低。
在本申请中，所述抗体可选择下组中任一项：单克隆抗体、单链抗体、嵌合抗体、鼠源抗体和人源化抗体。在本申请中，所述抗原结合片段可选自：Fab、Fab’、F(ab)2、F(ab’)2、Fv和scFv。
在本申请中，所述变体可选自下组：1)在所述抗体或所述其抗原结合片段中经过取代、缺失或添加一个或多个(例如，1-2个、1-3个、1-4个、1-5个、1-6个、1-7个、1-8个、1-9个、1-10个或更多个)氨基酸的蛋白质或多肽；和2)与所述抗体或所述其抗原结合片段具有90％以上(例如，具有至少约90％、约91％、约92％、约93％、约94％、约95％、约96％、约97％、约98％、约99％或更高的)序列同源性的蛋白质或多肽。在本申请中，所述变体与所述抗体、其抗原结合片段具有基本上相同的功能(例如，能够特异性结合CD19蛋白)。
在本申请中，所述抗体、其抗原结合片段或变体可与参比抗体竞争结合所述CD19蛋白。在本申请中，所述参比抗体可包含轻链可变区和重链可变区，所述参比抗体的轻链可变区可包含LCDR1-3，所述LCDR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:4和SEQ ID NO:18；所述LCDR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:5和SEQ ID NO:19；以及所述LCDR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:6和SEQ ID NO:20；且所述参比抗体的重链可变区可包含HCDR1-3，所述HCDR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:7、SEQ ID NO:21和SEQ ID NO:32；所述HCDR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:8、SEQ ID NO:22和SEQ ID NO:33；以及所述HCDR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:9、SEQ ID NO:23和SEQ ID NO:34。
在本申请中，所述参比抗体的轻链可变区的序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:42、SEQ ID NO:44和SEQ ID NO:46；所述参比抗体的重链可变区的序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:48、SEQ ID NO:50和SEQ ID NO:52。
本申请所述的抗体、其抗原结合片段或变体可包含抗体轻链或其片段。
在本申请中，所述轻链可包括轻链可变区，所述轻链可变区可包含LCDR1，所述LCDR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:4和SEQ ID NO:18。所述轻链可变区可包含LCDR2，所述LCDR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:5和SEQ ID NO:19。所述轻链可变区可包含LCDR3，所述LCDR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:6和SEQ ID NO:20。
在本申请中，所述抗体、其抗原结合片段或变体的轻链可变区可包含LFR1，所述LFR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:10、SEQ ID NO:24和SEQ ID NO:35。所述轻链可变区可包含LFR2，所述LFR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:11和SEQ ID NO:25。所述轻链可变区可包含LFR3，所述LFR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:12和SEQ ID NO:26。所述轻链可变区可包含LFR4，所述FR4的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:13、SEQ ID NO:27和SEQ ID NO:36。
在本申请中，所述轻链可变区的序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:42、SEQ ID NO:44和SEQ ID NO:46。
本申请所述的抗体、其抗原结合片段或变体可包含抗体重链或其片段。
在本申请中，所述轻链可包括重链可变区，所述重链可变区可包含HCDR1，所述HCDR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:7、SEQ ID NO:21和SEQ ID NO:32。所述重链可变区可包含HCDR2，所述HCDR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:8、SEQ ID NO:22和SEQ ID NO:33。所述重链可变区可包含HCDR3，所述HCDR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:9、SEQ ID NO:23和SEQ ID NO:34。
在本申请中，所述抗体、其抗原结合片段或变体的重链可变区可包含HFR1，所述HFR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:14、SEQ ID NO:28和SEQ ID NO:37。所述重链可变区可包含HFR2，所述HFR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:15、SEQ ID NO:29和SEQ ID NO:38。所述重链可变区可包含HFR3，所述HFR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:16、SEQ ID NO:30和SEQ ID NO:39。所述重链可变区可包含HFR4，所述HFR4的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:17、SEQ ID NO:31和SEQ ID NO:40。
在本申请中，所述重链可变区的序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:48、SEQ ID NO:50和SEQ ID NO:52。
在某些实施方式中，本申请所述的抗体或其抗原结合片段中LCDR1的氨基酸序列可包括SEQ ID NO:4或其变体；LCDR2的氨基酸序列可包括SEQ ID NO:5或其变体；LCDR3的氨基酸序列可包括SEQ ID NO:6或其变体；且HCDR1的氨基酸序列可包括SEQ ID NO:7或其变体；HCDR2的氨基酸序列可包括SEQ ID NO:8或其变体；HCDR3的氨基酸序列可包括SEQ ID NO:9或其变体。例如，该抗体或其抗原结合片段可包括抗体25C5-2或与其具有相同的LCDR1-3及HCDR1-3的抗体。本申请所述的抗体或其抗原结合片段中LFR1的氨基酸序列可包括SEQ ID NO:10或其变体；LFR2的氨基酸序列可包括SEQ ID NO:11或其变体；LFR3的氨基酸序列可包括SEQ ID NO:12或其变体；LFR4的氨基酸序列可包括SEQ ID NO:13或其变体；且HFR1的氨基酸序列可包括SEQ ID NO:14或其变体；HFR2的氨基酸序列可包括SEQ ID NO:15或其变体；HFR3的氨基酸序列可包括SEQ ID NO:16或其变体；HFR4的氨基酸序列可包括SEQ ID NO:17或其变体。例如，该抗体或其抗原结合片段可包括抗体25C5-2或与其具有相同的LFR1-4及HFR1-4的抗体。在某些实施方式中，本申请所述的抗体或其抗原结合片段的轻链可包含轻链可变区，所述轻链可变区的氨基酸序列可包括SEQ ID NO:42或其变体；且其中重链可包含重链可变区，所述重链可变区的氨基酸序列可包括SEQ ID NO:48或其变体。例如，该抗体或其抗原结合片段可包括抗体25C5-2或与其具有相同的轻链可变区及重链可变区的抗体。
例如，本申请所述抗体可为25C5-2。其中，抗体25C5-2的LCDR1-3的氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示；LFR1-4的氨基酸序列分别如SEQ ID NO:10、SEQ ID NO:11、SEQ ID NO:12和SEQ ID NO:13所示；VL的氨基酸序列如SEQ ID NO:42所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:7、SEQ ID NO:8和SEQ ID NO:9所示；HFR1-4的氨基酸序列分别如SEQ ID NO:14、SEQ ID NO:15、SEQ ID NO:16和SEQ ID NO:17所示；VH的氨基酸序列如SEQ ID NO:48所示。
在某些实施方式中，所述抗体25C5-2可以为scFv，所述scFv为VL-VH(即VL通过所述连接肽连接在VH的N端)，其中所述连接肽的氨基酸序列可以如SEQ ID NO:54所示。所述scFv的氨基酸序列可以如SEQ ID NO:56所示。
例如，本申请所述抗体可为10H10-1。其中，抗体10H10-1的LCDR1-3的氨基酸序列分别如SEQ ID NO:18、SEQ ID NO:19和SEQ ID NO:20所示；LFR1-4的氨基酸序列分别如SEQ ID NO:24、SEQ ID NO:25、SEQ ID NO:26和SEQ ID NO:27所示；VL的氨基酸序列如SEQ ID NO:44所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:21、SEQ ID NO:22和 SEQ ID NO:23所示；HFR1-4的氨基酸序列分别如SEQ ID NO:28、SEQ ID NO:29、SEQ ID NO:30和SEQ ID NO:31所示；VH的氨基酸序列如SEQ ID NO:50所示。
在某些实施方式中，所述抗体10H10-1可以为scFv，所述scFv为VL-VH(即VL通过所述连接肽连接在VH的N端)，其中所述连接肽的氨基酸序列可以如SEQ ID NO:54所示。所述scFv的氨基酸序列可以如SEQ ID NO:58所示。
例如，本申请所述抗体可为16F10。其中，抗体16F10的LCDR1-3的氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示；LFR1-4的氨基酸序列分别如SEQ ID NO:35、SEQ ID NO:11、SEQ ID NO:12和SEQ ID NO:36所示；VL的氨基酸序列如SEQ ID NO:46所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:32、SEQ ID NO:33和SEQ ID NO:34所示；HFR1-4的氨基酸序列分别如SEQ ID NO:37、SEQ ID NO:38、SEQ ID NO:39和SEQ ID NO:40所示；VH的氨基酸序列如SEQ ID NO:52所示。
在某些实施方式中，所述抗体16F10可以为scFv，所述scFv为VL-VH(即VL通过所述连接肽连接在VH的N端)，其中所述连接肽的氨基酸序列可以如SEQ ID NO:54所示。所述scFv的氨基酸序列可以如SEQ ID NO:60所示。
融合蛋白
另一方面，本申请提供了一种包含所述抗体、其抗原结合片段或变体的融合蛋白。在本申请中，所述融合蛋白可为嵌合抗原受体(CAR)，其可包括本申请所述的抗体和T细胞信号分子。例如，所述CAR可包括CD19结合结构域、跨膜结构域、铰链区、共刺激结构域和胞内信号转导结构域等结构域。
在本申请中，所述抗体可为单链抗体。在某些实施方式中，所述抗体可包含SEQ ID NO:56、SEQ ID NO:58、SEQ ID NO:60所示的氨基酸序列或其功能性变体。
例如，所述单链抗体可包括25C5-2，其氨基酸序列如SEQ ID NO:56所示。单链抗体25C5-2的LCDR1-3的氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示；VL的氨基酸序列如SEQ ID NO:42所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:7、SEQ ID NO:8和SEQ ID NO:9所示；VH的氨基酸序列如SEQ ID NO:48所示。
例如，所述单链抗体可包括10H10-1，其氨基酸序列如SEQ ID NO:58所示。单链抗体10H10-1的LCDR1-3的氨基酸序列分别如SEQ ID NO:18、SEQ ID NO:19和SEQ ID NO:20所示；VL的氨基酸序列如SEQ ID NO:44所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:21、SEQ ID NO:22和SEQ ID NO:23所示；VH的氨基酸序列如SEQ ID NO:50所示。
又例如，所述单链抗体可包括16F10，其氨基酸序列如SEQ ID NO:60所示。单链抗体 16F10的LCDR1-3的氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示；VL的氨基酸序列如SEQ ID NO:46所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:32、SEQ ID NO:33和SEQ ID NO:34所示；VH的氨基酸序列如SEQ ID NO:52所示。
在本申请中，所述CD19结合结构域可包含特异性结合CD19的抗体、抗原结合片段或变体。本申请所述的抗体、其抗原结合片段或变体可包含抗体轻链或其片段。所述轻链可包括轻链可变区，所述轻链可变区可包含LCDR1，LCDR2和LCDR3。所述LCDR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:4和SEQ ID NO:18。所述LCDR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:5和SEQ ID NO:19。所述LCDR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:6和SEQ ID NO:20。在本申请中，所述轻链可变区的序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:42、SEQ ID NO:44和SEQ ID NO:46。在本申请中，所述轻链可包括重链可变区，所述重链可变区可包含HCDR1，所述HCDR1的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:7、SEQ ID NO:21和SEQ ID NO:32。所述重链可变区可包含HCDR2，所述HCDR2的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:8、SEQ ID NO:22和SEQ ID NO:33。所述重链可变区可包含HCDR3，所述HCDR3的氨基酸序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:9、SEQ ID NO:23和SEQ ID NO:34。在本申请中，所述重链可变区的序列可选自下组中任一项所示的氨基酸序列或其变体：SEQ ID NO:48、SEQ ID NO:50和SEQ ID NO:52。
在本申请中，所述CAR可包括铰链区，其可连接所述抗体和所述跨膜结构域。例如，所述铰链区可选自CD8，其氨基酸序列如SEQ ID NO:62所示；也可选自IgG4，其氨基酸序列如SEQ ID NO:64所示。
在本申请中，所述CAR可包括跨膜结构域。例如，所述跨膜结构域可选自T细胞受体的α，β或ζ链、CD28、CD3e、CD45、CD4、CD5、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137和CD154等多肽。在本申请中，所述跨膜结构域可为CD8-1，其可包含SEQ ID NO:66所示的氨基酸序列或其功能性变体；也可为CD8-2，其可包含SEQ ID NO:68所示的氨基酸序列或其功能性变体。
在本申请中，所述CAR可包括共刺激域。例如，所述共刺激域可选自CD28、4-1BB、OX40和ICOS等多肽。在本申请中，所述共刺激域可为4-1BB，其可包含SEQ ID NO:70所示的氨基酸序列或其功能性变体；也可为OX40，其可包含SEQ ID NO:72所示的氨基酸序列或其功能性变体。
在本申请中，所述CAR可包括标记检测信号，所述标记检测信号可为荧光蛋白。例如，GFP、RFP或YFP。所述标记检测信号可位于所述CAR的C端。
在本申请中，所述CAR可包括Kozak序列，其核苷酸序列如SEQ ID NO:1所示。所述Kozak序列可位于CAR的N端。
在本申请中，所述CAR可包括前导序列，其核苷酸序列如SEQ ID NO:2所示(所述核苷酸序列不包括Kozak序列)。所述前导序列可位于CAR的N端。
在某些实施方式中，本申请所述CAR可自N端依次包括Kozak序列、前导序列、CD19结合结构域、跨膜结构域、共刺激结构域和胞内信号传导结构域。在某些是事实方式中，本申请所述CAR可自N端依次包括Kozak序列、前导序列、CD19结合结构域、跨膜结构域、共刺激结构域、胞内信号传导结构域和标记检测信号。
例如，本申请所述的CAR可以为CAR25C5-2，其LCDR1-3的氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示；VL的氨基酸序列如SEQ ID NO:42所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:7、SEQ ID NO:8和SEQ ID NO:9所示；VH的氨基酸序列如SEQ ID NO:48所示；VH与VL之间的连接肽的序列如SEQ ID NO:54所示；其Kozak序列的核苷酸序列如SEQ ID NO:1所示；其前导序列的氨基酸序列如SEQ ID NO:3所示；其铰链区的氨基酸序列如SEQ ID NO:62所示；其跨膜结构域的氨基酸序列如SEQ ID NO:66所示；其共刺激结构域的氨基酸序列如SEQ ID NO:70所示；其CD3ζ胞内信号传导结构域的氨基酸序列如SEQ ID NO:74所示。
又例如，本申请所述CAR可以为CAR10H10-1，其LCDR1-3的氨基酸序列分别如SEQ ID NO:18、SEQ ID NO:19和SEQ ID NO:20所示；VL的氨基酸序列如SEQ ID NO:44所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:21、SEQ ID NO:22和SEQ ID NO:23所示；VH的氨基酸序列如SEQ ID NO:50所示；VH与VL之间的连接肽的氨基酸序列如SEQ ID NO:54所示；其Kozak序列的核苷酸序列如SEQ ID NO:1所示；其前导序列的氨基酸序列如SEQ ID NO:3所示；其铰链区的氨基酸序列如SEQ ID NO:62所示；其跨膜结构域的氨基酸序列如SEQ ID NO:66所示；其共刺激结构域的氨基酸序列如SEQ ID NO:70所示；其CD3ζ胞内信号传导结构域的氨基酸序列如SEQ ID NO:74所示。
又例如，本申请所述CAR可以为CAR16F10，其LCDR1-3的氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示；VL的氨基酸序列如SEQ ID NO:46所示；HCDR1-3的氨基酸序列分别如SEQ ID NO:32、SEQ ID NO:33和SEQ ID NO:34所示；VH的氨基酸序列如SEQ ID NO:52所示；VH与VL之间的连接肽的氨基酸序列如SEQ ID NO:54所示；其Kozak序列的核苷酸序列如SEQ ID NO:1所示；其前导序列的氨基酸序列如SEQ ID NO:3 所示；其铰链区的氨基酸序列如SEQ ID NO:62所示；其跨膜结构域的氨基酸序列如SEQ ID NO:66所示；其共刺激结构域的氨基酸序列为如SEQ ID NO:70所示；其CD3ζ胞内信号传导结构域的氨基酸序列如SEQ ID NO:74所示。
核酸分子、载体、细胞及制备方法
另一方面，本申请提供了分离的一种或多种核酸分子，其可编码本申请所述的抗体、其抗原结合片段或变体，和/或，其编码所述的融合蛋白。本申请所述编码抗体的分离的核酸分子可包含SEQ ID NO:55、SEQ ID NO:57、SEQ ID NO:59所示的核酸序列或其功能性变体。本申请所述的核酸分子可以为分离的。例如，其可以是通过以下方法产生或合成的：(i)在体外扩增的，例如通过聚合酶链式反应(PCR)扩增产生的，(ii)通过克隆重组产生的，(iii)纯化的，例如通过酶切和凝胶电泳分级分离，或者(iv)合成的，例如通过化学合成。在某些实施方式中，所述分离的核酸是通过重组DNA技术制备的核酸分子。
另一方面，本申请提供了一种或多种载体，其可包含本申请所述的一种或多种核酸分子。在本申请中，所述载体可为PXC17.4或pCDNA3.4。例如，PXC17.4或pCDNA3.4载体可包含SEQ ID NO:55、SEQ ID NO:57、SEQ ID NO:59所示的核酸序列或其功能性变体。此外，所述载体中还可包含其他基因，例如允许在适当的宿主细胞中和在适当的条件下选择该载体的标记基因。此外，所述载体还可包含允许编码区在适当宿主中正确表达的表达控制元件。这样的控制元件为本领域技术人员所熟知的，例如，可包括启动子、核糖体结合位点、增强子和调节基因转录或mRNA翻译的其他控制元件等。在某些实施方式中，所述表达控制序列为可调的元件。所述表达控制序列的具体结构可根据物种或细胞类型的功能而变化，但通常包含分别参与转录和翻译起始的5’非转录序列和5’及3’非翻译序列，例如TATA盒、加帽序列、CAAT序列等。例如，5’非转录表达控制序列可包含启动子区，启动子区可包含用于转录控制功能性连接核酸的启动子序列。本申请所述的一种或多种核酸分子可以与所述表达控制元件可操作地连接。所述载体可以包括，例如质粒、粘粒、病毒、噬菌体或者在例如遗传工程中通常使用的其他载体。
另一方面，本申请提供了一种或多种细胞，其可包含本申请所述的一种或多种核酸分子或本申请所述的一种或多种载体。在本申请中，所述细胞可选自PBMC、CD4、CD8、NK等细胞。在某些实施方式中，每种或每个细胞可包含一个或一种本申请所述的载体。在某些实施方式中，每种或每个细胞可包含多个(例如，2个或以上)或多种(例如，2种或以上)本申请所述的载体。在本申请中，可将所述载体引入免疫效应细胞中可通过本领域已知的方法将本申请所述的载体引入所述细胞中。在本申请中，可通过本领域已知的方法将本申请所述 的载体引入所述细胞中，例如电穿孔、脂质体法转染(lipofectamine 2000，Invitrogen)等。例如，可以通过Bio-Rad的电转导工具进行电转导。又例如可以通过Gibco的转染试剂盒进行转导。
另一方面，本申请提供了制备本申请所述的抗体、其抗原结合片段或变体，和/或本申请所述的融合蛋白的方法，所述方法可包括在使得本申请所述抗体、其抗原结合片段或变体，和/或本申请所述的融合蛋白表达的条件下，培养本申请所述的细胞，还可包含收获所述抗体、其抗原结合片段或变体，和/或，所述的融合蛋白。
药物组合物、制药用途
另一方面，本申请提供了一种药物组合物，其可包含本申请所述的抗体、其抗原结合片段或变体、本申请所述的核酸分子、本申请所述的载体、本申请所述的细胞和/或本申请所述的融合蛋白，以及任选地药学上可接受的佐剂。所述药学上可接受的佐剂可以包括缓冲剂、抗氧化剂、防腐剂、低分子量多肽、蛋白质、亲水聚合物、氨基酸、糖、螯合剂、反离子、金属复合物和/或非离子表面活性剂等。在本申请中，所述药物组合物可被配制用于口服给药，静脉内给药(例如，静脉注射，I.V.)，肌肉内给药(例如，肌肉注射，I.M.)，在肿瘤部位的原位给药，吸入，直肠给药，阴道给药，经皮给药(例如，皮下注射，I.C.)或通过皮下储存库给药。
另一方面，本申请提供了所述的抗体、其抗原结合片段或变体，和/或，所述的融合蛋白在制备预防或治疗疾病或病症的药物中的用途，其中所述药物用于治疗肿瘤和自体免疫疾病。
另一方面，本申请提供了所述的抗体、其抗原结合片段或变体，和/或，所述的融合蛋白，其治疗肿瘤和自体免疫疾病。
另一方面，本申请提供了一种治疗肿瘤和自体免疫疾病的方法，包括向患者施用所述的抗体、其抗原结合片段或变体，和/或，所述的融合蛋白。
在某些实施方式中，所述肿瘤选自下组中的任一项：B细胞亚型非霍奇金氏恶性淋巴瘤(NHL)、伯基特氏淋巴瘤、多发性骨髓瘤、前B急性淋巴母细胞性白血病及其他来源于早期B细胞前体的恶性肺瘤、普通急性淋巴细胞白血病、T慢性淋巴细胞性白血病、毛细胞白血病、非急性淋巴母细胞性白血病、华氏巨球蛋白血症、前淋巴细胞性白血病、浆细胞瘤、骨硬化骨髓瘤、浆细胞性白血病、单克隆丙种球蛋白病(MGUS)、郁积性多发性骨髓瘤(SMM)、缓慢性多发性骨髓瘤(IMM)、霍奇金氏恶性淋巴瘤、胃癌、肝癌、白血病、肾脏肿瘤、肺癌、小肠癌、骨癌、前列腺癌、结直肠癌、乳腺癌、大肠癌、前列腺癌、宫颈癌、肾上腺肿瘤和膀胱肿瘤。在某些实施方式中，所述自体免疫疾病选自下组中的任一项：类风 湿性关节炎、多发性硬化症和CD19 +白血病。
另一方面，本申请提供了一种抑制CD19蛋白生物学活性的方法，其包括施用本申请所述的抗体、其抗原结合片段或变体、本申请所述的核酸分子、本申请所述的载体、本申请所述的细胞和/或本申请所述的融合蛋白。
另一方面，本申请提供了本申请所述的抗体、其抗原结合片段或变体、本申请所述的核酸分子、本申请所述的载体、本申请所述的细胞和/或本申请所述的融合蛋白在制备诊断或检测肿瘤的试剂中的应用。在某些实施方式中，所述诊断或检测肿瘤的试剂可以特异性地识别CD19蛋白和/或带有CD19蛋白的癌细胞。在某些实施方式中，所述诊断或检测肿瘤的试剂就可以通过酶联免疫法，化学发光法，免疫比浊法等方法进行体外诊断。例如，所述检测可以通过酶联免疫吸附法进行，将肿瘤标记物CD19蛋白作为固定相，与待测样品共同竞争本申请所述抗体。在某些实施方式中，所述诊断或检测肿瘤的试剂可以同辣根过氧化酶的底物反应显色，用于诊断肿瘤。
不欲被任何理论所限，下文中的实施例仅仅是为了阐释本申请的装置、方法和系统的工作方式，而不用于限制本申请发明的范围。
实施例
实施例1 CD19抗体的制备
1.1免疫实验动物
为产生CD19抗体，用纯化的重组CD19蛋白(ACRO，CD9-H52H2)和CD19 +Ramos细胞(ATCC)免疫六周龄Babl/c雌鼠(湖南斯莱克生物技术有限公司)，所用小鼠为SPF级(无特定病原体，specfic pathogen free)。可根据重组蛋白皮下免疫和Ramos细胞(购自ATCC)腹腔注射免疫对小鼠进行免疫，小鼠第一次输注抗原后为六周龄。第一次免疫使用重组CD19蛋白和弗氏完全佐剂(购自Sigma)免疫按v:v＝1:1的比例充分混匀后进行四肢皮下免疫，每只50μg。一周后进行第二次免疫，使用重组CD19蛋白和弗氏非完全佐剂(购自Sigma)按v:v＝1:1的比例充分混匀后进行四肢皮下免疫，每只50μg。一周后进行第三次免疫，使用Ramos细胞(购自ATCC)进行腹腔免疫。收集Ramos细胞，用无血清RPMI-1640培养基(购自Sigma)洗涤两遍，将细胞密度稀释至10 7个/mL。然后向每只小鼠皮下注射1mL Ramos细胞溶液进行免疫。一周后再进行第四次免疫，用所述的Ramos细胞溶液进行免疫，向每只小鼠皮下注射1mL Ramos细胞溶液进行免疫。第四次免疫后一周取眼球血，用ELISA检测血清抗体滴度，抗体的稀释度若不小于10 5，则免疫完成；若抗体稀释度大于10 5，则用上述重组CD19蛋白和弗氏非完全佐剂(购自Sigma)按v:v＝1:1的比例充分混匀后再进行四 肢皮下免疫，每只50μg，然后再次进行检测，直到免疫完成。
1.2杂交瘤细胞的融合与筛选
为筛选生产特异性结合CD19的抗体的Babl/c免疫小鼠，通过如Fishwild等人(1996)所述的ELISA测试免疫的小鼠的血清。简而言之，取实施例1.2中经重组CD19蛋白免疫后血清抗体稀释度达到10 5以上的小鼠，脱颈处死后去脾脏，用70μm的筛网(corning)将脾脏研碎分离得到单个B细胞，按照1:10的比例将B细胞和SP2/0细胞混合，借助PEG(购自Sigma)将B细胞和SP2/0细胞融合成杂交瘤细胞。将融合后的细胞按照每孔200μL的量分装到96孔细胞培养板中，共计30块96孔细胞培养板。将96孔细胞培养板放在37℃、5％CO 2细胞培养箱(Thermo 150i)中培养，然后通过如Fishwild等人(1996)所述的ELISA来筛选分泌高活性抗体的融合细胞株。
将溶于PBS中的1ng/μL的纯化的重组CD19包被ELISA检测板(购自厦门怡佳美)，每孔100μL。在37℃温育2小时后，然后溶于PBS/Tween(0.05％)中的5％鸡血清封闭，每孔280μL，然后于37℃温育2小时后备用。向每个孔中加入100μL来自杂交瘤融合细胞上清液，然后在37℃环境温度温育30分钟。用PBS/Tween洗涤平板5次，然后每孔加入100μL与辣根过氧化物酶(HRP)缀合的山羊-抗-人IgG Fc多克隆抗体37℃温育30分钟。然后用PBS/Tween洗涤5次后，每孔加入100μL TMB显色液(山东淄博云桥生物技术有限公司)，37℃温育5分钟后加入50μL 2M的硫酸终止反应，并通过酶标仪(波长450nm)读取OD值，取OD值高于1.0的杂交瘤融合细胞株，通过有限稀释法筛选符合条件的可特异性结合CD19的单克隆细胞株(参见张越，屈会化，吴婷婷，等。甘草酸单克隆抗体的制备与鉴定[J].药物分析杂志,2013,33(5):770-774.)。
1.3抗CD19不同表位及亲和力抗体筛选
通过杂交瘤融合技术筛选到三株具有不同亲和力和结合表位的抗CD19鼠源抗体，分别命名为25C5-2，10H10-1和16F10。通过Sanger高通量测序技术测序(参见Tsiatis A C,Norris-Kirby A,Rich R G等人.Comparison of Sanger sequencing,pyrosequencing,and melting curve analysis for the detection of KRAS mutations:diagnostic and clinical implications[J].The Journal of Molecular Diagnostics,2010,12(4):425-432.)获得三株抗体的重链和轻链可变区核苷酸序列，其中25C5-2的VL氨基酸序列如SEQ ID NO:42所示，其VH氨基酸序列如SEQ ID NO:48所示；10H10-1的VL氨基酸序列如SEQ ID NO:44所示，其VH氨基酸序列如SEQ ID NO:50所示；16F10的VL氨基酸序列如SEQ ID NO:46所示，其VH氨基酸序列如SEQ ID  NO:52所示。
1.4人工合成scFv形式的CD19抗体
人工合成VL与VH之间的连接肽VL-VH连接肽，其核苷酸序列如SEQ ID NO:53所示。并且人工合成上一步中测序得到的三株可特异性结合CD19的抗体的VL和VH的核苷酸序列，然后首位连接构建scFv形式的CD19抗体。
具体而言，为获得25C5-2抗体，首先合成其VL，其核苷酸序列如SEQ ID NO:41所示；然后合成VL-VH连接肽，其核苷酸序列如SEQ ID NO:53所示；然后合成其VH，其核苷酸序列如SEQ ID NO:47所示。将VL、VL-VH连接肽和VL的核苷酸序列依次首尾连接获得完整的25C5-2scFv序列，其核苷酸序列如SEQ ID NO:55所示。
相似地，为获得10H10-1抗体，首先合成其VL，其核苷酸序列如SEQ ID NO:43所示；然后合成VL-VH连接肽，其核苷酸序列如SEQ ID NO:53所示；然后合成其VH，其核苷酸序列如SEQ ID NO:49所示。将VL、VL-VH连接肽和VH的核苷酸序列依次首尾连接获得完整的10H10-1scFv序列，其核苷酸序列如SEQ ID NO:57所示。
相似地，为获得16F10抗体，首先合成其VL，其核苷酸序列如SEQ ID NO:45所示；然后合成VL-VH连接肽，其核苷酸序列如SEQ ID NO:53所示；然后合成其VH，其核苷酸序列如SEQ ID NO:51所示。将VL、VL-VH连接肽和VL的核苷酸序列依次首尾连接获得完整的16F10scFv序列，其核苷酸序列如SEQ ID NO:59所示。
1.5载体的构建与抗体表达
将上一步合成的scFv基因通过大肠杆菌扩增后提取质粒，利用BamHI和SaiL酶切后连入表达载体PXC17.4等，利用Bio-Rad的电转导工具进行电穿孔，将表达载体导入CHO细胞进行表达，随后对所述抗体的表达情况进行检测。
实施例2 CD19抗体活性检测(ELISA)
运用ELISA法检测实施例1中制得CD19抗体。取CD19蛋白(购自acro)100μg，加入300μL超纯水(超纯水仪购自PALL)充分溶解，获得浓度为0.33μg/μL的CD19蛋白稀释液。按照每孔100ng的量包被96孔检测板。
用PBS缓冲溶液将CD19蛋白稀释至1μg/μL，取40mL；并取上述用超纯水溶解的CD19蛋白120μL CD19蛋白到40mL PBS缓冲溶液中，将两者充分混匀后按照每孔100μL的量加入到96孔检测板中，于37℃温育2小时。温育完成后除去96孔板中残余的蛋白溶液，在每 孔中加入280μL(1％BSA+PBS)封闭液，37℃温育2小时后4℃保存备用。
取实施例1中制得的抗体16F10、25C5-2、10H10-1进行检测，并以FMC-63(Merck，选择MAB1794)作为阳性对照(本申请所有实施例所使用的anti-CD19阳性对照均是FMC-63,其scfv核苷酸序列请参见CN201180067173.X SEQ ID NO.14，氨基酸序列为SEQ ID NO.20)，以不加一抗、二抗作为阴性对照。
将待检测抗体用PBS统一稀释到0.1mg/mL的浓度备用。按照倍比稀释的方法在检测板中加入100μL的PBS。在第一个检测孔中加入100μL稀释的0.1mg/mL抗体溶液，充分混匀后依次取100μL到下一个梯度，类似地进行11个梯度稀释，每个样品重复一次。稀释完成的检测板，于37℃温育30分钟。
温育完成后洗板5次，每次280μL，洗板完成后，轻轻拍板几次以除干净残余的洗液。然后，按照每孔100μL的量加入配置好的羊抗人二抗稀释液(羊抗人二抗购自abcam，按照1:10000的比例用PBS稀释)，于37℃温育30分钟后洗板。洗板完成后按照每孔100μL加入TMB显色液，于37℃温育5分钟按照每孔50μL的量加入2M硫酸终止液，终止反应。置MD-M2E(美国分子仪器公司)酶标仪上读取450nm处的OD值，应用软件MD-M2E进行数据处理。结果如图1所示。结果显示，10H10-1与CD19蛋白的亲和力最强，即使在低浓度情况下依然有很强的结合能力，16F10、25C5-2的检测结果类似。
实施例3 CD19抗体活性检测
3.1细胞处理
收集NALM-6细胞到50mL离心管中，以400g离心5分钟离心收集细胞，取20mL预冷至4℃的PBS重悬细胞，离心收集细胞，按照该方法将细胞用PBS洗涤三次后，用13mL PBS重悬细胞后计数，细胞浓度为3.92×10 6个/mL，细胞存活率为98％。将细胞按照每管600μL分装到流式检测管中备用，共计25支。
3.2 CD19抗体稀释
将CD19抗体按照如下梯度用PBS稀释。具体操作如下：取实施例1中制得的抗体16F10、10H10-1、25C5-2将其各自分别稀释至50μg/mL、10μg/mL、5μg/mL、2.5μg/mL、1.25μg/mL。取200μL加入到离心收集的细胞沉淀中重悬细胞，于4℃反应1小时后离心收集细胞用PBS洗涤三次。反应完成后，按照以400g的速度于4℃离心5min，收集细胞，加入1mL预冷至4℃的PBS按照上述离心条件离心洗涤两遍，后收集细胞沉淀弃上清。
3.3二抗孵育
将FITC标记的羊抗鼠抗体(Abcam Goat Anti-Mouse IgG H&L(FITC)ab6785)按照1:300(PBS稀释)的比例稀释后，每个检测管中每管加入500μL的FITC标记的羊抗鼠抗体稀释液重悬细胞，FITC标记的羊抗鼠抗体对照组也加入500μLFITC标记的羊抗鼠抗体稀释液，阴性对照组加入500μL PBS，4℃孵育1小时后，按照上述方法用PBS洗涤细胞三次，最后用200μL PBS重悬洗涤离心后的细胞，以用于流式检测。
3.4流式检测
首先将从上一步骤中获得的细胞重悬于PBS缓冲液中，加入实施例1中获得的CD19抗体16F10、10H10-1、25C5-2，以不加一抗、二抗作为阴性对照。
流式检测电压按下述步骤进行设置：在流式鞘液桶中装入足量鞘液后，开机流式细胞仪(BD verse)预热20分钟后，打开流式检测软件，设置FSC/SSC的去黏连，在FSC和SSC检测图中画适当的检测门，设置检测门的细胞检测量为10 4个，再画第二个检测图FSC-A和FSC-H的检测图，定义第二个检测图上的检测细胞来自P1门，并在第二个检测图上设置合适的P2门，设置第三个检测图COUNT和FITC-A，定义第三个图的检测数据来自P2门，相关检测图绘制完成后，用对照NALM-6细胞设置检测电压使NALM-6细胞显示在第一个检测图的中心位置，FITC-A的检测信号在10 1-10 2之间后，开始检测NALM-6细胞，收集数据设置对照组，保存检测电压和相关参数后开始检测样品检测，记录相关数据。取16F10、10H10-1、25C5-2抗体浓度5μg/mL、FMC63浓度0.025μg/mL的结果作图，结果如图2所示。
结果显示，16F10、25C5-2、10H10-1都具有相似的对表达在肿瘤细胞NALM-6表面的CD19结合能力，其中16F10的结合能力最强，其次是10H10-1和25C5-2。
实施例4 CD19抗体蛋白印迹法检测
取浓度为1mg/mL CD19胞外区蛋白(购自abcam，ab234966，氨基酸序列编号第20位至291位)10μL，与10mL 2×的加样缓冲液(其包含20mM DTT)，充分混匀，于95℃沸水浴5分钟。然后按照现有技术中的常规操作进行SDS-PAGE电泳实验(含12％的SDS)，从实施1中获得的CD19抗体10H10-1、25C5-1进行电泳测试，并以不加一抗和二抗作为阴性对照，在电泳时使用的标记物Marker购自全式金，目录号：DM201，lot:K51027，每种样品加样5μL。在电泳时。使用浓缩胶(5％的浓缩胶，2mL，纯化水1.4mL、30％Acr-Bis 0.33mL、1M pH8.8 Tris 0.25mL、12％SDS(十二烷基磺酸钠)0.02mL、10％过硫酸铵0.02ml、TEMED(四甲基二乙胺)0.002mL)进行浓缩，浓缩时电压为100V；使用分离胶(10％的浓缩胶，5 mL，纯化水1.3mL、30％Acr-Bis 1.7mL、1M pH8.8Tris 1.9mL、12％SDS(十二烷基磺酸钠)0.05mL、10％过硫酸铵0.05mL、TEMED(四甲基二乙胺)0.002mL)进行分离，分离时电压为140V。当溴酚蓝到达胶底部时停止电泳。
于100V恒定电压进行转膜，转膜时间为45分钟。将聚偏二氟乙烯(PVDF)膜放入5％脱脂奶粉溶液(PBST溶液配置)中封闭1小时，用PBST溶液洗涤3次，每次在侧摆摇床上缓慢摇动洗涤5分钟左右。封闭完成后将实施例1中获得的CD19抗体10H10-1、25C5-1以及阳性对照FMC-63，用PBST稀释到20μg/mL的浓度后与5％脱脂奶封闭的PVDF膜室温反应1小时，然后用PBST洗涤三次，每次在侧摆摇床上缓慢摇动洗涤5min左右。PBST洗涤完成后加入用1:5000PBST稀释的HRP标记的羊抗鼠二抗，于室温反应45min后，反应完成后用PBST洗涤三次，每次洗涤5分钟左右。添加ECL发光液(购自BIO-RAD)拍片来检测蛋白，采集时曝光时间为1秒。
结果如图3所示，结果显示10H10-1可以和变性的CD19重组蛋白反应，阳性对照FMC63和25C5-2与变性的CD19重组蛋白不反应。
实施例5 CD19 scfv抗体流式检测
5.1细胞处理
取与实施例3中相同的NALM-6细胞，将NALM-6细胞收集到15ml离心管中，以400g的速度离心5分钟收集细胞，弃去上清液，用与所弃上清液等体积的PBS缓冲溶液重悬离心收集的细胞，重复3次后用10mL PBS缓冲溶液重悬细胞。取PBS洗涤后的细胞悬液20μl加入到无菌的1.5ml离心管中，再加入等体积台盼蓝轻轻混匀后取20μL加入到Count Sart细胞计数板中，将计数板放入Count Sart细胞计数仪中，点击细胞计数后读取数据。计数得到细胞浓度为5.37×10 5/mL。然后将洗涤后的细胞悬液分装到流式检测管中，每管1mL。预留一管作为阴性对照。
5.2 CD19 scfv抗体稀释
将待检测的CD19抗体10H10-1、25C5-2分别用PBS稀释到200μg/mL的浓度，然后分别各自按照1:20、1:80、1:320、1:1280、1:5120的比例稀释至10μg/mL、2.5μg/mL、0.625μg/mL、0.312μg/mL、0.156μg/mL，然后加入到1mL NALM-6的细胞悬液中，充分混匀后4℃反应2小时。按照400g的速度于4℃离心5分钟收集细胞，加入1mL预冷至4℃的PBS缓冲溶液。按照上述离心条件离心洗涤两遍，后收集细胞沉淀弃上清，在细胞沉淀中加入预先按照1:1000稀释的PE标记的羊抗人抗体，于4℃反应1h。反应完成后，按照400g的速度于4℃离心5min 收集细胞，加入1mL预冷至4℃的PBS缓冲溶液按照上述离心条件离心洗涤两遍后收集细胞沉淀，弃去上清液，最后用200μL PBS缓冲溶液重悬洗涤离心后的细胞，做流式检测用。
5.3流式检测
首先将从上一步骤中获得的细胞重悬于PBS缓冲液中，加入实施例1中获得的CD19抗体10H10-1、25C5-2的scFv，以不加一抗、二抗作为阴性对照。
流式检测电压按下述步骤进行设置：在流式鞘液桶中装入足量鞘液后，开机流式细胞仪(BD verse)预热20分钟后，打开流式检测软件，设置FSC/SSC的去黏连，在FSC和SSC检测图中画适当的检测门，设置检测门的细胞检测量为10 4个，再画第二个检测图FSC-A和FSC-H的检测图，定义第二个检测图的检测细胞来自P1门，并在第二个检测图上设置合适的P2门，设置第三个检测图COUNT和FITC-A，定义第三个图的检测数据来自P2门，相关检测图绘制完成后，用对照NALM-6细胞设置检测电压使NALM-6细胞显示在第一个检测图的中心位置，FITC-A的检测信号在10-10 2之间后，开始检测NALM-6细胞，收集数据设置对照组，保存检测电压和相关参数后开始检测样品检测，记录相关数据。
结果如图4所示，25C5-2、10H10-1都有明显的结合CD19阳性细胞的能力,其中10H10-1的结合能力最强，其次是25C5-2。
实施例6 Anti-CD19CAR-T构建及阳性率检测
6.1合成anti-CD19CAR结构
得到的anti-CD19scfv和不同的功能区组成CAR结构后通过基因合成的方法获得CAR结构(CAR结构示意图如图5所示)
其中，leader的核苷酸序列如SEQ ID NO.2所示；铰链区(Hinge)的核苷酸序列如SEQ ID NO.61所示，跨膜结构(TM)的核苷酸序列如SEQ ID NO.65所示，4-1BB的核苷酸序列如SEQ ID NO.69所示，OX40的核苷酸序列如SEQ ID NO.71所示，CD3zeta的核苷酸序列如SEQ ID NO.73所示。本申请筛选获得的anti-CD19scfv，以10H10-1(SEQ ID NO.57)和25C5-2(SEQ ID NO.55)为例构建CAR-T，并同时构建阳性药CAR-T(anti-CD19scfv为FMC-63(Merck))
合成基因借助大肠扩增后提取质粒利用BamHI和SaiL酶切后连入表达载体通过stabl3扩增提质粒，为构建CAR-T细胞准备质粒
6.2 T细胞分离激活
利用Ficoll试剂法分离采集全血中的PBMC细胞，通过磁珠阴选的方法分离CD4+和CD8+T细胞，在分离的T细胞中按照1:1(个数比)的比例加入激活磁珠CD3/CD28，T细胞激活24小时进行电转试验。
6.3电转构建CAR-T细胞
将构建好的anti-CD19CAR-T表达载体按照3.3μg对应4×10 6个T细胞的量配制电转条件按照一起设置的程序电转后收集T细胞，24小时检测CAR-T细胞阳性率及CAR-T细胞杀伤活力。
6.4流式检测CAR-T细胞的阳性率
收集培养24小时后的电转T细胞，PBS洗涤3遍后按照10 6个细胞一管的量分装到不同的流式检测管中，按照10 6个细胞加入2μLFITC标记的CD19蛋白4℃抚育2小时后，PBS洗涤3次，用300μLPBS重悬细胞后上流式检测CAR-T细胞的阳性率。结果如图6所示。
实施例7 Anti-CD19CAR-T肿瘤杀伤活性检测
7.1靶细胞标记
收集对数生长期NALM-6，用0.01MPBS洗涤细胞一次。再用完全培养基将细胞重悬为密度1×10 6cell/mL悬液。取3mL该细胞悬液，加入5μLBATDA并充分混匀，37℃，5％CO 2条件下孵育5min。
用清洗液(1×PBS+20mMHepes)洗涤标记的NALM-6细胞4次。末次清洗后将细胞重悬于完全培养基中，并将细胞密度调节至8×10 4cell/mL。
2、效靶细胞共孵育
待上述1)靶细胞重悬后，立即取适量细胞悬液离心后，取上清作为背景测试孔。
取1)的细胞悬液100μL(8000cell/well)接种于96wellV-bottom板中。最大释放孔加入含1％TritonX-100100μL完全培养基溶液，自发释放孔加入100μL完全培养基溶液，试验孔加入效应细胞100μL(效靶比1:1)。
孵育1-4h后，500g室温离心5min。
3、细胞杀伤活性测定
取20μL上清液至平底96孔板中，加入200μLEuropium Solution。
室温避光振荡混匀15min。
利用HTRF法测定荧光值(激发光340nm，发射光615nm)。
4、数据处理
按下式计算受试细胞杀伤率(％)：
细胞杀伤率(％)＝(试验孔读数-自发释放孔读数)/(最大释放孔读数-自发释放孔读数)×100
5、如表1结果所示，以25C5为例构建的CAR-T比阳性对照具有更强的杀伤活力。
表1 CD19-CAR-T对NALM-6杀伤率(％,(Mean±SEM,n＝3)
Figure PCTCN2019122486-appb-000002
前述详细说明是以解释和举例的方式提供的，并非要限制所附权利要求的范围。目前本申请所列举的实施方式的多种变化对本领域普通技术人员来说是显而易见的，且保留在所附的权利要求和其等同方案的范围内。

Claims (39)

  1. 抗体、其抗原结合片段或变体，其以3.5μg/mL或更低的IC50值与CD19蛋白相结合。
  2. 根据权利要求1所述的抗体、其抗原结合片段或变体，所述抗体选自下组中任一项：单克隆抗体、单链抗体、嵌合抗体、鼠源抗体和人源化抗体。
  3. 根据权利要求1-2中任一项所述的抗体、其抗原结合片段或变体，所述抗原结合片段选自：Fab、Fab’、F(ab)2、F(ab’)2、Fv和scFv。
  4. 根据权利要求1-3中任一项的抗体、其抗原结合片段或变体，所述变体选自下组：
    1)在所述抗体或所述其抗原结合片段中经过取代、缺失或添加一个或多个氨基酸的蛋白质或多肽；和
    2)与所述抗体或所述其抗原结合片段具有90％以上序列同源性的蛋白质或多肽。
  5. 抗体、其抗原结合片段或变体，其与参比抗体竞争结合所述CD19蛋白，其中所述参比抗体包含轻链可变区和重链可变区，所述参比抗体的轻链可变区包含LCDR1-3，所述LCDR1的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:4和SEQ ID NO:18；所述LCDR2的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:5和SEQ ID NO:19；以及所述LCDR3的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:6和SEQ ID NO:20；且，
    所述参比抗体的重链可变区包含HCDR1-3，所述HCDR1的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:7、SEQ ID NO:21和SEQ ID NO:32；所述HCDR2的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:8、SEQ ID NO:22和SEQ ID NO:33；以及所述HCDR3的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:9、SEQ ID NO:23和SEQ ID NO:34。
  6. 根据权利要求5所述的抗体、其抗原结合片段或变体，其中所述参比抗体的轻链可变区的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:42、SEQ ID NO:44和SEQ ID NO:46，且所述参比抗体的重链可变区的氨基酸序列选自下组中任一项所示的氨基酸序列：SEQ ID NO:48、SEQ ID NO:50和SEQ ID NO:52。
  7. 抗体、其抗原结合片段或变体，其包含LCDR1，且所述LCDR1包含选自下组任一项所示的氨基酸序列：SEQ ID NO:4和SEQ ID NO:18。
  8. 根据权利要求7中所述的抗体、其抗原结合片段或变体，其包含LCDR2，且所述LCDR2包含选自下组任一项所示的氨基酸序列：SEQ ID NO:5和SEQ ID NO:19。
  9. 根据权利要求7或8中所述的抗体、其抗原结合片段或变体，其包含LCDR3，且所述LCDR3包含选自下组任一项所示的氨基酸序列：SEQ ID NO:6和SEQ ID NO:20。
  10. 根据权利要求7-9中任一项所述的抗体、其抗原结合片段或变体，其包含轻链可变区VL，且所述轻链可变区VL包含选自下组任一项所示的氨基酸序列：SEQ ID NO:42、SEQ ID NO:44和SEQ ID NO:46。
  11. 根据权利要求7-10中任一项所述的抗体、其抗原结合片段或变体，其包含HCDR1，且所述HCDR1包含选自下组任一项所示的氨基酸序列：SEQ ID NO:7、SEQ ID NO:21、SEQ ID NO:32。
  12. 根据权利要求7-11中任一项所述的抗体、其抗原结合片段或变体，其包含HCDR2，且所述HCDR2包含选自下组任一项所示的氨基酸序列：SEQ ID NO:8、SEQ ID NO:22和SEQ ID NO:33。
  13. 根据权利要求7-12中任一项所述的抗体、其抗原结合片段或变体，其包含HCDR3，且所述HCDR3包含选自下组任一项所示的氨基酸序列：SEQ ID NO:9、SEQ ID NO:23和SEQ ID NO:34。
  14. 根据权利要求7-13中任一项所述的抗体、其抗原结合片段或变体，其包含重链可变区VH，且所述重链可变区VH包含选自下组任一项所示的氨基酸序列：SEQ ID NO:48、SEQ ID NO:50和SEQ ID NO:52。
  15. 根据权利要求1-14中任一项所述的抗体、其抗原结合片段或变体，其中所述抗体或其抗原结合片段为scFv。
  16. 根据权利要求15所述的抗体、其抗原结合片段或变体，其中所述scFv包含选自下组任一项所示的氨基酸序列：SEQ ID NO:56、SEQ ID NO:58和SEQ ID NO:60。
  17. 根据权利要求1-16中任一项所述的抗体、其抗原结合片段或变体，其中所述CD19蛋白为人CD19蛋白。
  18. 融合蛋白，其包含权利要求1-17中任一项所述的抗体、其抗原结合片段或变体。
  19. 根据权利要求18所述的融合蛋白，其中所述融合蛋白为嵌合抗原受体。
  20. 根据权利要求19所述的融合蛋白，其中所述嵌合抗原受体包含胞外铰链区、跨膜结构域、共刺激结构域和CD3ζ胞内信号转导结构域。
  21. 根据权利要求20所述的融合蛋白，其中所述胞外铰链区选自CD8铰链或IgG4铰链。
  22. 根据权利要求20或21所述的融合蛋白，其中所述跨膜结构域选自T细胞受体的α，β或ζ链、CD28、CD3e、CD45、CD4、CD5、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137和CD154。
  23. 根据权利要求22所述的融合蛋白，其中所述跨膜结构域选自CD8-1或CD8-2。
  24. 根据权利要求20-23任意一项所述的融合蛋白，其中所述共刺激结构域选自CD27、CD28、4-1BB、OX40或ICOS。
  25. 根据权利要求20-24任意一项所述的融合蛋白，其中所述的嵌合抗原受体，所述胞外铰链区选自CD8铰链或IgG4铰链；所述跨膜结构域选自CD8-1或CD8-2；所述共刺激结构域选自4-1BB或OX40。
  26. 根据权利要求25所述的融合蛋白，其中所述的嵌合抗原受体，所述CD8-1跨膜的N端与所述CD8铰链的C端相连，所述CD8-1跨膜的C端与所述4-1BB的N端相连，所述4-1BB的C端与所述OX40的N端相连，所述OX40的C端与所述CD3ζ的N端相连。
  27. 根据权利要求25所述的融合蛋白，其中所述的嵌合抗原受体，所述CD8-2跨膜的N端与所述IgG4铰链的C端相连，所述CD8-2跨膜的C端与所述4-1BB的N端相连，所述4-1BB的C端与所述OX40的N端相连，所述OX40的C端与所述CD3ζ的N端相连。
  28. 分离的一种或多种核酸分子，其编码权利要求1-17中任一项所述的抗体、其抗原结合片段或变体，和/或，其编码权利要求18-27中任一项所述的融合蛋白。
  29. 一种或多种载体，其包含权利要求28所述的一种或多种核酸分子。
  30. 一种或多种细胞，其包含权利要求28所述的一种或多种核酸分子或权利要求29所述的一种或多种载体。
  31. 制备权利要求1-17中任一项所述的抗体、其抗原结合片段或变体，和/或，权利要求18-28中任一项所述的融合蛋白的方法，所述方法包括在使得权利要求1-17中任一项所述抗体、其抗原结合片段或变体，和/或，权利要求18-27中任一项所述的融合蛋白表达的条件下，培养权利要求30所述的细胞。
  32. 根据权利要求31所述的方法，其包含收获所述抗体、其抗原结合片段或变体，和/或，所述的融合蛋白。
  33. 药物组合物，其包含权利要求1-17中任一项所述的抗体、其抗原结合片段或变体、权利要求18-27中任一项所述的融合蛋白、权利要求28所述的核酸分子、权利要求29所述的载体，和/或，权利要求30所述的细胞，以及任选地药学上可接受的佐剂。
  34. 权利要求1-17中任一项所述的抗体、其抗原结合片段或变体，和/或，权利要求18-27中任一项所述的融合蛋白在制备预防或治疗疾病或病症的药物中的用途。
  35. 根据权利要求34所述的用途，所述疾病或病症选自下组中的任一项：肿瘤和自体免疫疾病。
  36. 根据权利要求35所述的用途，所述肿瘤选自下组中的任一项：B细胞亚型非霍奇金氏恶性淋巴瘤(NHL)、伯基特氏淋巴瘤、多发性骨髓瘤、前B急性淋巴母细胞性白血病及其他来源于早期B细胞前体的恶性肺瘤、普通急性淋巴细胞白血病、T慢性淋巴细胞性白血病、毛细胞白血病、非急性淋巴母细胞性白血病、华氏巨球蛋白血症、前淋巴细胞性白血病、浆细胞瘤、骨硬化骨髓瘤、浆细胞性白血病、单克隆丙种球蛋白病(MGUS)、郁积性多发性骨髓瘤(SMM)、缓慢性多发性骨髓瘤(IMM)、霍奇金氏恶性淋巴瘤、胃癌、肝癌、白血病、肾脏肿瘤、肺癌、小肠癌、骨癌、前列腺癌、结直肠癌、乳腺癌、大肠癌、前列腺癌、宫颈癌、肾上腺肿瘤和膀胱肿瘤。
  37. 根据权利要求36所述的用途，所述自体免疫疾病选自下组中的任一项：类风湿性关节炎、多发性硬化症和CD19+白血病。
  38. 抑制CD19蛋白生物学活性的方法，其包括施用权利要求1-17中任一项所述的抗体、其抗原结合片段或变体、权利要求18-27中任一项所述的融合蛋白、权利要求28所述的核酸分子、权利要求29所述的载体，和/或，权利要求30所述的细胞。
  39. 权利要求1-17中任一项所述的抗体、其抗原结合片段或变体、权利要求18-27中任一项所述的融合蛋白、权利要求28所述的核酸分子、权利要求29所述的载体，和/或，权利要求30所述的细胞，在制备诊断或检测肿瘤的试剂中的应用。
PCT/CN2019/122486 2018-12-03 2019-12-02 Cd19抗体及其应用 Ceased WO2020114358A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201811465547 2018-12-03
CN201811465547.3 2018-12-03
CN201910740771.7 2019-08-12
CN201910740771 2019-08-12

Publications (1)

Publication Number Publication Date
WO2020114358A1 true WO2020114358A1 (zh) 2020-06-11

Family

ID=70945072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/122486 Ceased WO2020114358A1 (zh) 2018-12-03 2019-12-02 Cd19抗体及其应用

Country Status (2)

Country Link
CN (1) CN111253487B (zh)
WO (1) WO2020114358A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390894A (zh) * 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
KR102393776B1 (ko) * 2020-12-30 2022-05-04 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
CN117616048A (zh) * 2021-07-09 2024-02-27 先声再明医药有限公司 Cd19抗体及其应用
CN119954967A (zh) * 2023-05-19 2025-05-09 优恺泽生物医药(上海)有限公司 免疫效应细胞及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105950645A (zh) * 2016-01-11 2016-09-21 灏灵赛奥（天津）生物科技有限公司 Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
CN106536564A (zh) * 2014-06-02 2017-03-22 美国卫生和人力服务部 靶向cd‑19的嵌合抗原受体
CN106800601A (zh) * 2017-01-19 2017-06-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CN106922147A (zh) * 2014-08-28 2017-07-04 朱诺治疗学股份有限公司 Cd19特异性抗体和嵌合抗原受体
CN107312091A (zh) * 2017-05-02 2017-11-03 重庆精准生物技术有限公司 靶向人cd19抗原的人源化单克隆抗体
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN108047332A (zh) * 2018-01-15 2018-05-18 浙江阿思科力生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
CN108330133A (zh) * 2017-01-20 2018-07-27 上海恒润达生生物科技有限公司 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途
US10125193B2 (en) * 2014-02-14 2018-11-13 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125193B2 (en) * 2014-02-14 2018-11-13 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
CN106536564A (zh) * 2014-06-02 2017-03-22 美国卫生和人力服务部 靶向cd‑19的嵌合抗原受体
CN106922147A (zh) * 2014-08-28 2017-07-04 朱诺治疗学股份有限公司 Cd19特异性抗体和嵌合抗原受体
CN105950645A (zh) * 2016-01-11 2016-09-21 灏灵赛奥（天津）生物科技有限公司 Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
CN106800601A (zh) * 2017-01-19 2017-06-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CN108330133A (zh) * 2017-01-20 2018-07-27 上海恒润达生生物科技有限公司 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途
CN107312091A (zh) * 2017-05-02 2017-11-03 重庆精准生物技术有限公司 靶向人cd19抗原的人源化单克隆抗体
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN108047332A (zh) * 2018-01-15 2018-05-18 浙江阿思科力生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用

Also Published As

Publication number Publication date
CN111253487A (zh) 2020-06-09
CN111253487B (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
TWI830151B (zh) 抗GPRC5DxBCMAxCD3三特異性抗體及其用途
CN113603785B (zh) 新的间皮素抗体和包含其的组合物
US9663568B2 (en) Antibodies that bind peptidoglycan recognition protein 1
WO2017049452A1 (zh) 抗人cd137的完全人抗体及其应用
WO2020114358A1 (zh) Cd19抗体及其应用
WO2023179716A1 (zh) 一种抗cd3抗体、其制备方法及应用
CN111936516B (zh) 新型抗egfr抗体多肽
KR102249981B1 (ko) 단클론성 항-gpc-1 항체 및 이의 용도
JP2026510879A (ja) クローディン１８．２に特異的に結合する抗体、その調製方法及びその応用
CN115386007A (zh) 抗gprc5d抗体、其制备方法与用途
CN116964100A (zh) Gucy2c结合多肽及其用途
Li et al. Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library
WO2025026358A1 (zh) Muc1结合分子和包含其的嵌合抗原受体
CN117561278A (zh) 抗trem2人源化抗体、其抗原结合片段及其应用
CN118271451A (zh) 靶向crtam和pd-l1的抗体及其应用
CN118515777A (zh) 双价或多价抗体的构建体、其建立方法及应用
CN113121689B (zh) Ctla-4结合分子及其用途
WO2022166700A1 (zh) 基于ccdc112抑制肿瘤细胞生长的方法
CN112867733B (zh) 抗cd137抗体及其应用
CN115838424A (zh) 靶向tigit的单克隆抗体
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2025015713A1 (zh) 抗trem2人源化抗体、其抗原结合片段及其应用
WO2025061149A1 (zh) 抗gcc抗体、嵌合抗原受体及其用途
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
WO2025030887A1 (zh) 抗trem2纳米抗体或其抗原结合片段及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19894020

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19894020

Country of ref document: EP

Kind code of ref document: A1